Entero Therapeutics (ENTO) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-37853
Entity Registrant Name	Entero Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4993860
Entity Address, Address Line One	777 Yamato Road, Suite 502
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	589-7020
Entity Information, Former Legal or Registered Name	First Wave BioPharma, Inc.
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	ENTO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,754,030
Entity Central Index Key	0001604191
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 366,788	$ 3,711,770
Prepaid expenses	305,461	1,244,466
Assets of disposal group held for sale	83,170,009
Total Current Assets	83,842,258	4,956,236
Property, equipment, and leasehold improvements, net		14,565
Other Assets:
Restricted cash	21,520	21,522
Goodwill	1,684,182	1,684,182
Operating lease right-of-use assets	144,410	195,440
Deposits	128,250	11,250
Total Other Assets	1,978,362	1,912,394
Total Assets	85,820,620	6,883,195
Current Liabilities:
Accounts payable	2,214,946	554,277
Accrued expenses	219,193	825,290
Accrued dividend payable	1,258,450	1,069,616
Note payable		612,784
Operating lease liabilities	79,454	67,111
Other current liabilities		4,239
Liabilities of disposal group held for sale	11,918,261
Total Current Liabilities	15,690,304	3,133,317
Non-current operating lease liabilities	80,213	146,949
Total Liabilities	15,770,517	3,280,266
Mezzanine Equity:
Total Mezzanine Equity	61,681,100
Stockholders' Equity:
Common stock - Par value $0.0001 per share; 100,000,000 shares authorized; 4,741,964 and 1,560,998 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	474	156
Additional paid-in capital	198,518,268	187,931,445
Accumulated deficit	(190,149,739)	(184,328,672)
Total Stockholders' Equity	8,369,003	3,602,929
Total Liabilities, Mezzanine Equity and Stockholders' Equity	85,820,620	6,883,195
Series G redeemable preferred stock
Mezzanine Equity:
Total Mezzanine Equity	61,681,100
Series B preferred stock
Stockholders' Equity:
Preferred stock	0	0
Series C Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series D Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series E Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series F Preferred Stock
Stockholders' Equity:
Preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	4,741,964	1,560,998
Common stock, shares outstanding (in shares)	4,741,964	1,560,998
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000
Series G redeemable preferred stock
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized	13,000	13,000
Temporary Equity, Shares Issued	12,373.226	0
Temporary Equity, Shares Outstanding	12,373.226	0
Series B preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,194.81	5,194.81
Preferred stock, shares issued (in shares)	484.52	514.96
Preferred stock, shares outstanding (in shares)	484.52	514.96
Series C Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	75,000	75,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	150	150
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series E Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	150	150
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series F Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	7,000	7,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development expenses	$ 206,999	$ 1,011,055	$ 882,522	$ 3,725,833
General and administrative expenses	1,685,608	2,422,082	13,535,241	7,951,373
Total operating expenses	1,892,607	3,433,137	14,417,763	11,677,206
Loss from operations	(1,892,607)	(3,433,137)	(14,417,763)	(11,677,206)
Other expenses:
Interest income (expense), net	229	(1,021)	675	(13,108)
Other expense, net	(2,874)		(7,859)	(3,729)
Total other expenses	(2,645)	(1,021)	(7,184)	(16,837)
Loss before income tax benefit	(1,895,252)	(3,434,158)	(14,424,947)	(11,694,043)
Income tax benefit			10,604,640
Net loss from continuing operations	(1,895,252)	(3,434,158)	(3,820,307)	(11,694,043)
Loss from discontinued operations	(685,719)		(2,000,760)
Net loss	(2,580,971)	(3,434,158)	(5,821,067)	(11,694,043)
Preferred stock dividends	(84,632)	(49,292)	(150,776)	(231,047)
Net loss applicable to common shareholders	$ (2,665,603)	$ (3,483,450)	$ (5,971,843)	$ (11,925,090)
Weighted average shares outstanding, basic (in shares)	4,552,019	378,301	3,005,055	188,175
Weighted average shares outstanding, diluted (in shares)	4,552,019	378,301	3,005,055	188,175
Loss per share, basic	$ (0.59)	$ (9.21)	$ (1.99)	$ (63.37)
Loss per share, diluted	(0.59)	$ (9.21)	(1.99)	$ (63.37)
Loss per share from discontinued operations, basic	(0.15)		(0.67)
Loss per share from discontinued operations, diluted	$ (0.15)		$ (0.67)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Mezzanine Equity and Changes in Stockholders' Equity (unaudited) - USD ($)	Issuance of Common Stock, Pre Funded Warrants in July 2023 Offering Common Stock	Issuance of Common Stock, Pre Funded Warrants in July 2023 Offering Additional Paid-in Capital	Issuance of Common Stock, Pre Funded Warrants in July 2023 Offering	July 2024 Inducement Offering Common Stock	July 2024 Inducement Offering Additional Paid-in Capital	July 2024 Inducement Offering	June 2023 inducement offering Common Stock	June 2023 inducement offering Additional Paid-in Capital	June 2023 inducement offering	September 2023 inducement offering Common Stock	September 2023 inducement offering Additional Paid-in Capital	September 2023 inducement offering	Private placement Common Stock	Private placement Additional Paid-in Capital	Private placement	Convertible preferred stock Series G Convertible Preferred Stock	Convertible preferred stock Series B Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning (in shares) at Dec. 31, 2022																	550	49,750
Balance at the beginning at Dec. 31, 2022																		$ 5	$ 171,275,836	$ (168,533,689)	$ 2,742,152
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings and private placement, net of issuance costs	$ 3	$ 1,833,924	$ 1,833,927										$ 1	$ 3,690,972	$ 3,690,973
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings and private placement, net of issuance costs (in shares)	30,500												6,400
Exercise of pre-funded warrants into Common Stock																		$ 21	636		657
Exercise of pre-funded warrants into Common Stock (in shares)																		199,974
Issuance of common stock in connection with the exercise of warrants, net of offering costs							$ 8	$ 2,239,057	$ 2,239,065	$ 29	$ 3,706,742	$ 3,706,771
Issuance of Common Stock in connection with the exercise of warrants, net of offering costs (in shares)							86,216			294,101
Deemed dividend of Series B preferred stock																			(231,047)		(231,047)
Conversion of Series B preferred shares into common stock (in shares)																	(28)	26
Common stock issued to consultants																			76,000		76,000
Common stock issued to consultants (in shares)																		2,500
Issuance of common stock from RSU vest (in shares)																		3,854
Effect of cancelled shares from the reverse stock split (in shares)																		(147)
Stock-based compensation																			914,350		914,350
Net loss																				(11,694,043)	(11,694,043)
Balance at the end (in shares) at Sep. 30, 2023																	522	673,174
Balance at the end at Sep. 30, 2023																		$ 67	183,506,470	(180,227,732)	3,278,805
Balance at the beginning (in shares) at Jun. 30, 2023																	546	210,450
Balance at the beginning at Jun. 30, 2023																		$ 21	177,675,513	(176,793,574)	881,960
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings and private placement, net of issuance costs	$ 3	$ 1,833,924
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings and private placement, net of issuance costs (in shares)	30,500
Exercise of pre-funded warrants into Common Stock																		$ 14	253		267
Exercise of pre-funded warrants into Common Stock (in shares)																		133,750
Issuance of common stock in connection with the exercise of warrants, net of offering costs										$ 29	$ 3,706,742	$ 3,706,771
Issuance of Common Stock in connection with the exercise of warrants, net of offering costs (in shares)										294,101
Deemed dividend of Series B preferred stock																			(49,292)		(49,292)
Conversion of Series B preferred shares into common stock (in shares)																	(24)	22
Common stock issued to consultants																		$ 2,500	76,000		76,000
Issuance of common stock from RSU vest (in shares)																		1,851
Deemed dividend related to exchange of Series B preferred stock			$ 1,833,927
Stock-based compensation																			263,330		263,330
Net loss																				(3,434,158)	(3,434,158)
Balance at the end (in shares) at Sep. 30, 2023																	522	673,174
Balance at the end at Sep. 30, 2023																		$ 67	183,506,470	(180,227,732)	3,278,805
Mezzanine Equity - Balance at the beginning (in shares) at Dec. 31, 2023																0
Mezzanine Equity - Balance at the beginning at Dec. 31, 2023																$ 0
Balance at the beginning (in shares) at Dec. 31, 2023																	515	1,560,998
Balance at the beginning at Dec. 31, 2023																	$ 0	$ 156	187,931,445	(184,328,672)	3,602,929
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings and private placement, net of issuance costs																		$ 44	4,495,482		4,495,526
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings and private placement, net of issuance costs (in shares)																		448,100
Issuance of stock upon acquisition of IMGX																$ 57,790,474		$ 4	2,300,496		2,300,500
Issuance of stock upon acquisition of IMGX (in shares)																11,777		36,830
Issuance of stock to financial advisors																$ 3,890,626		$ 2	120,646		120,648
Issuance of stock to financial advisors (in shares)																596		18,475
Exercise of pre-funded warrants into Common Stock																		$ 45			45
Exercise of pre-funded warrants into Common Stock (in shares)																		443,525
Issuance of common stock in connection with the exercise of warrants, net of offering costs				$ 176	$ 1,730,189	$ 1,730,365
Issuance of Common Stock in connection with the exercise of warrants, net of offering costs (in shares)				1,762,674
Deemed dividend of Series B preferred stock																			(188,834)		(188,834)
Conversion of Series B preferred shares into common stock (in shares)																	(30)	27
Common stock issued to consultants																		$ 35	1,541,960		1,541,995
Common stock issued to consultants (in shares)																		350,000
Issuance of common stock from RSU vest																		$ 12	(12)
Issuance of common stock from RSU vest (in shares)																		121,335
Stock-based compensation																			586,896		586,896
Net loss																				(5,821,067)	(5,821,067)
Mezzanine Equity - Balance at the end (in shares) at Sep. 30, 2024																12,373
Mezzanine Equity - Balance at the end at Sep. 30, 2024																$ 61,681,100					61,681,100
Balance at the end (in shares) at Sep. 30, 2024																	485	4,741,964
Balance at the end at Sep. 30, 2024																		$ 474	198,518,268	(190,149,739)	8,369,003
Mezzanine Equity - Balance at the beginning (in shares) at Jun. 30, 2024																12,373
Mezzanine Equity - Balance at the beginning at Jun. 30, 2024																$ 61,681,100
Balance at the beginning (in shares) at Jun. 30, 2024																	485	2,941,108
Balance at the beginning at Jun. 30, 2024																		$ 294	196,689,069	(187,568,768)	9,120,595
Issuance of common stock in connection with the exercise of warrants, net of offering costs				$ 176	$ 1,730,189	$ 1,730,365
Issuance of Common Stock in connection with the exercise of warrants, net of offering costs (in shares)				1,762,674
Deemed dividend of Series B preferred stock																			(84,632)		(84,632)
Issuance of common stock from RSU vest																		$ 4	(4)
Issuance of common stock from RSU vest (in shares)																		38,182
Stock-based compensation																			183,646		183,646
Net loss																				(2,580,971)	(2,580,971)
Mezzanine Equity - Balance at the end (in shares) at Sep. 30, 2024																12,373
Mezzanine Equity - Balance at the end at Sep. 30, 2024																$ 61,681,100					61,681,100
Balance at the end (in shares) at Sep. 30, 2024																	485	4,741,964
Balance at the end at Sep. 30, 2024																		$ 474	$ 198,518,268	$ (190,149,739)	$ 8,369,003

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Mezzanine Equity and Changes in Stockholders' Equity (unaudited) (Parenthetical)			9 Months Ended
	Dec. 18, 2023	Jan. 18, 2023	Sep. 30, 2023
Condensed Consolidated Statements of Mezzanine Equity and Changes in Stockholders' Equity (unaudited)
Reverse stock split ratio	0.05	0.143	0.143

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (5,821,067)	$ (11,694,043)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	48,946	21,955
Amortization of debt discount	5,848
Change in right-of-use assets	55,262	47,429
Stock-based compensation	586,896	914,350
Common stock granted to consultants	1,541,995	76,000
Common stock issued to financial advisors at acquisition	120,648
Series G convertible preferred stock issued to financial advisors at acquisition	3,890,626
Deferred taxes	(10,604,640)
Changes in assets and liabilities:
Other receivables		93,014
Prepaid expenses	939,005	1,272,558
Lease liabilities	(58,004)	(48,919)
Deposits	(117,000)	6,899
Accounts payable	900,546	(140,749)
Accrued expenses	(531,127)	514,364
Other liabilities	(4,239)	(1,332)
Net cash used in operating activities	(9,046,305)	(8,938,474)
Cash flows from investing activities:
Cash acquired in acquisition of IMGX	88,169
Net cash provided by investing activities	88,169
Cash flows from financing activities:
Proceeds from issuance of common stock, prefunded warrants and warrants, net	4,495,526	5,525,010
Proceeds from the issuance of common stock in connection with the exercise of warrants in the July 2024 Inducement Offering, net	1,730,365
Proceeds from exercise of warrants, net of issuance costs		5,946,383
Proceeds from exercise of pre-funded warrants	45
Repayments of note payable	(644,582)	(603,494)
Proceeds from note payable	31,798
Net cash provided by financing activities	5,613,152	10,867,899
Net (decrease) increase in cash, cash equivalents and restricted cash	(3,344,984)	1,929,425
Cash, cash equivalents and restricted cash, beginning balance	3,733,292	1,384,423
Cash, cash equivalents and restricted cash, ending balance	388,308	3,313,848
Supplemental disclosures of cash flow information:
Cash paid for interest	30,468	15,414
Non-cash investing and financing activities:
Fair value of common shares issued in the IMGX acquisition, net of cash	152,331
Fair value of the Series G preferred stock issued in the IMGX acquisition	57,790,474
Fair value of options assumed in the IMGX acquisition	1,271,000
Fair value of warrants assumed in the IMGX acquisition	789,000
Accrued dividends on preferred stock	$ (188,834)	$ (231,047)

The Company and Basis of Presen

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
The Company and Basis of Presentation
The Company and Basis of Presentation	Note 1 - The Company and Basis of Presentation The Company Entero Therapeutics, Inc. (“ Entero FWB IMGX GI In May 2024, the Company changed its name from First Wave Biopharma, Inc. to Entero Therapeutics, Inc. In March 2024, the Company acquired ImmunogenX, Inc. (“ ImmunogenX Merger GFDs The Company is seeking avenues to dispose of certain assets and liabilities of IMGX within 12 months of the date of the Merger, including Latiglutenase and CypCel. As of September 30, 2024, these were classified as assets and liabilities held for sale and due to the short period of time since the close of the Merger and are reported at their fair value less cost to sell. The Company determined that the discontinued operations of IMGX represents a strategic shift that will have a major effect on the Company’s operations and financial statements. See Note 3 for additional details regarding the Merger and see Note 4 for additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations. The Company’s development pipeline consists of gut-restricted GI clinical drug candidates, including the biologic Adrulipase (formerly MS1819), a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company plans to pursue for GI indications. The Company is exploring strategic alternatives for its Niclosamide program, an oral small molecule with anti-viral and anti-inflammatory properties. All of the Company’s programs are currently on hold due to capital constraints. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund clinical trials and operations. Worldwide supply chain constraints and economic and capital markets uncertainty arising out of conflicts between Russia and Ukraine and conflicts in the Middle East triggered by attacks on Israel in October of 2023 have disrupted commercial and capital markets and emerged as new barriers to long-term economic recovery. Capital markets uncertainty, with public stock price decreases and volatility, could make it more difficult for us to raise capital when needed. In addition, the Company is subject to other challenges and risks specific to its business, its ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the biotechnology and pharmaceutical industries with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its drug candidates; delays or problems in the manufacture and supply of its drug candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or drug candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2023, has been derived from audited financial statements of that date. The unaudited interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our Annual Report Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024. Substantial Doubt about the Company’s Ability to Continue as a Going Concern The accompanying unaudited interim condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. On September 30, 2024, the Company had cash and cash equivalents of approximately $0.4 million and an accumulated deficit of approximately $190.1 million. The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. Based on its cash on hand at September 30, 2024, the Company anticipates having sufficient cash to fund planned operations into December 2024. Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its capital stock. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. The Company has been, and is expected to continue, exploring various potential strategies available including but not limited to raising capital, restructuring its indebtedness and identifying and evaluating potential strategic alternatives but there can be no assurance that these efforts will be successful, that the Company will be able to raise necessary capital on acceptable terms, reach agreement with lenders, or that the strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. The Company is evaluating all potential strategic options, including a merger, reverse merger, sale, wind-down, liquidation and dissolution or other strategic transaction. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stakeholder value or that it will make any cash distributions to stockholders. Any failure in these efforts could force the Company to delay, limit or terminate operations, make reductions in its workforce, discontinue research and development programs, liquidate all or a portion of assets or pursue other strategic alternatives, and/or seek protection under the provisions of the U.S. Bankruptcy Code. Without adequate working capital, the Company may not be able to meet its obligations and continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern one year from the date these financial statements are issued. If the Company is not able to obtain necessary capital, it may be required to terminate operations, liquidate all or a portion of assets and/or seek bankruptcy protection. As a result, the Company concluded that its plans at this stage do not alleviate substantial doubt about the ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2024
Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies and Recent Accounting Pronouncements	Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements Use of Estimates The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates. Reverse Stock Split On December 18, 2023, the Company effected a reverse stock split, whereby every twenty On January 18, 2023, the Company effected a reverse stock split, whereby every seven All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. All cash and cash equivalent balances were highly liquid at September 30, 2024 and December 31, 2023. As of September 30, 2024 and December 31, 2023, the Company has classified approximately $0.02 million as restricted cash. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At September 30, 2024 the Company had approximately $0.4 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions. Fair Value Measurements The Company follows Accounting Standards Codification ( ASC ( ASC 820 As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Goodwill Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through September 30, 2024 related to goodwill. ​ Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment ( ASC 360 Income Taxes Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ ASC 740 The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At September 30, 2024 and 2023, the Company does not have any significant uncertain tax positions. Leases Leases are recorded on the balance sheet as right of use assets and lease obligations. Lease liabilities are recognized based on the present value of the future minimum lease payments over the least term at the commencement date. Leases with a term of 12 months or less at inception are expensed monthly over the lease term. The lease term is determined by assuming the exercise of renewal options that are reasonably certain. The implicit interest rate or the incremental borrowing rate is used in determining the present value of future payments. Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“ CROs CDMOs CMC Research and Development – The Company records intellectual property acquired in business acquisitions that has not reached technological feasibility and which has no alternative future use, as In-Process R&D (“ IPR&D ​ Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its Consolidated Statements of Operations. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test that compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. The Company has not recognized any impairment charges through September 30, 2024 related to IPR&D. For tax purposes, intangible assets related to IPR&D are considered indefinite-lived intangible assets. Stock-Based Compensation The Company’s board of directors (the “ Board 2014 Plan 2020 Plan IMGX Plan ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Assets Held for Sale and Discontinued Operations Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the condensed consolidated balance sheet. A newly acquired business in a business combination that has met the held for sale criteria should be measured at fair value less costs to sell. This is because the business has been recently acquired and its carrying value has been adjusted to its fair value. Depreciation and amortization of assets cease upon designation as held for sale. Discontinued operations comprise activities that were disposed of, discontinued or held for sale at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes, and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, Presentation of Financial Statements. Additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations are included in Note 4. Recent Accounting Pronouncements The Company has evaluated recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective, will not have a material impact on the Company’s financial position or results of operations upon adoption.

Business Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2024
Business Acquisition
Business Acquisition	Note 3 – Business Acquisition On March 13, 2024, the Company acquired ImmunogenX, Inc., a Delaware corporation, in accordance with the terms of an Agreement and Plan of Merger, dated March 13, 2024 (the “ Merger Agreement First Merger Sub Second Merger Sub First Merger Second Merger IMGX Merger Under the terms of the Merger Agreement, following the consummation of the Merger (the “ Closing issued The Company incurred transaction costs of $5,456,038 which are included in the Company’s condensed consolidated statement of operations. In addition, the Company assumed (i) all ImmunogenX stock options immediately outstanding prior to the First Merger, each becoming an option to purchase Common Stock subject to adjustment pursuant to the terms of the Merger Agreement (the “ Assumed Options Assumed Warrants Tungsten Partners LLC (“ Tungsten The Merger was accounted for as a business combination under the acquisition method of accounting with First Wave as the accounting acquirer. Under the acquisition method, the total purchase price of the acquisition is allocated to the net identifiable tangible and intangible assets acquired and liabilities assumed based on the fair values as of the date of such acquisition. The preliminary fair value of the consideration totaled approximately $60.1 million, summarized as follows: ​ ​ ​ ​ ​ ​ Amount Common stock issued to ImmunogenX stockholders ​ $ 240,500 Replacement options ​ 1,271,000 Replacement warrants ​ 789,000 Preferred stock issued to ImmunogenX stockholders ​ 57,790,474 Total consideration paid ​ $ 60,090,974 ​ The Company has made a provisional allocation of the purchase price of the Merger to the assets acquired and the liabilities assumed as of the purchase date. The following table summarizes the provisional purchase price allocations relating to the Merger: ​ ​ ​ ​ ​ Assets acquired: ​ ​ Cash and cash equivalents ​ $ 88,169 Prepaid expenses and other current assets ​ 3,131,929 Property and equipment, net ​ 18,963 Intangibles ​ 63,370,000 Operating lease right-of-use assets ​ 4,232 Total assets ​ $ 66,613,293 Liabilities assumed: ​ Accounts payable ​ 916,209 Accrued expenses and other current liabilities ​ 2,131,439 Long term debt ​ 6,397,889 Deferred tax liability ​ 13,760,280 Total liabilities ​ $ 23,205,817 Goodwill recorded: ​ ​ ​ Goodwill ​ $ 16,683,498 Net assets acquired ​ $ 60,090,974 ​ The fair value of IPR&D was capitalized as of the IMGX Merger date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the IMGX Merger is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of such acquisition. The goodwill recorded is not deductible for tax purposes. All intangible assets acquired are subject to amortization and their associated estimated acquisition date fair values are as follows: ​ ​ ​ ​ ​ ​ ​ ​ Estimated Acquisition Date Intangible Asset ​ Useful Life ​ Fair Value Patents 2 years ​ $ 140,000 Trade names and trademarks 6 years ​ 230,000 IPR&D – Latiglutenase Indefinite ​ 54,000,000 IPR&D - CypCel Indefinite ​ $ 9,000,000 ​ Net loss in the Condensed Consolidated Statement of Operations for the nine months ended September 30, 2024 includes net losses of IMGX from the date of acquisition to September 30, 2024 of approximately $2.0 million, which is classified as discontinued operations. The Merger is classified as held for sale as of September 30, 2024. Refer to Note 4 for further information. Pro forma disclosure for the IMGX acquisition The following unaudited pro forma financial information reflects the consolidated results of operations of the Company as if the Acquisition had taken place on January 1, 2024. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Nine Months ​ ​ Ended September 30, 2024 ​ Ended September 30, 2024 Operating expenses ​ $ 1,892,607 ​ $ 14,417,763 Loss before income tax benefit ​ (1,895,252) ​ (14,424,947) Loss from discontinued operations ​ (685,719) ​ (9,374,674) Net loss applicable to common shareholders ​ ​ (2,665,603) ​ ​ (13,345,757) ​ ​ ​ ​ ​ ​ ​ Basic and diluted weighted average shares outstanding ​ 4,552,019 ​ 3,005,055 Loss per share - basic and diluted ​ $ (0.59) ​ $ (4.44) ​

Discontinued Operations and Ass

Discontinued Operations and Assets and Liabilities Held for Sale	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Assets and Liabilities Held for Sale
Discontinued Operations and Assets and Liabilities Held for Sale	Notes 4 – Discontinued Operations and Assets and Liabilities Held for Sale The Company has initiated a plan to dispose of certain assets and liabilities of IMGX within 12 months of the date of the Merger with IMGX. These are classified as assets and liabilities held for sale and, due to the short period of time since the close of the Merger, are reported at their fair value less cost to sell. The Company determined that the discontinued operations of IMGX represents a strategic shift that will have a major effect on the Company’s operations and financial statements. The following table summarizes the Company’s loss from discontinued operations for the three and nine months ended September 30, 2024 and 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2024 2023 2024 2023 Operating expenses: ​ ​ ​ ​ Research and development expenses ​ $ 301,661 ​ $ — ​ $ 1,225,533 ​ $ — General and administrative expenses ​ 76,971 ​ — ​ 152,187 ​ — Total operating expenses ​ 378,632 ​ — ​ 1,377,720 ​ — Interest expense ​ (305,614) ​ — ​ (670,296) ​ — Other (expense) income ​ (1,473) ​ — ​ 47,256 ​ — Loss from discontinued operations ​ $ (685,719) ​ $ — ​ $ (2,000,760) ​ $ — ​ The assets and liabilities associated with discontinued operations consist of the following as of September 30, 2024: ​ ​ ​ ​ Assets held for sale: ​ Prepaid expenses and other current assets ​ $ 3,131,929 Property and equipment, net ​ 16,180 Goodwill and intangible assets ​ 80,021,900 Total assets held for sale ​ $ 83,170,009 Liabilities held for sale: ​ Accounts payable ​ $ 156,086 Accrued expenses and other current liabilities ​ 2,202,798 Debt ​ 6,403,737 Deferred tax liability ​ ​ 3,155,640 Total liabilities held for sale ​ $ 11,918,261 ​ Total assets and liabilities classified as held for sale are presented as current assets and liabilities, respectively, as they are anticipated to be sold within 12 months.

Fair Value Disclosures

Fair Value Disclosures	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures
Fair Value Disclosures	Note 5 - Fair Value Disclosures Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measured at Reporting Date ​ ​ ​ ​ ​ ​ ​ ​ Using ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount Level 1 Level 2 Level 3 Fair Value September 30, 2024 (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 12,573 ​ $ 12,573 ​ $ — ​ $ — ​ $ 12,573 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 12,131 ​ $ 12,131 ​ $ — ​ $ — ​ $ 12,131 Note payable ​ ​ 612,784 ​ ​ — ​ ​ 612,784 ​ $ — ​ ​ 612,784 ​ At September 30, 2024 and December 31, 2023, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.

Property, Equipment and Leaseho

Property, Equipment and Leasehold Improvements	9 Months Ended
	Sep. 30, 2024
Property, Equipment and Leasehold Improvements
Property, Equipment and Leasehold Improvements	Note 6 – Property, Equipment and Leasehold Improvements Property, equipment and leasehold improvements consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2024 December 31, ​ ​ (unaudited) ​ 2023 Computer equipment and software ​ $ 11,540 ​ $ 11,540 Office equipment ​ 48,278 ​ 48,278 Leasehold improvements ​ 28,000 ​ 28,000 Total property, equipment and leasehold improvements ​ 87,818 ​ 87,818 Less accumulated depreciation ​ (87,818) ​ (73,253) Property, equipment and leasehold improvements, net ​ $ — ​ $ 14,565 ​ Depreciation expense for the three months ended September 30, 2024 and 2023 was approximately $1,000 and $7,000. Depreciation expense for the nine months ended September 30, 2024 and 2023 was approximately $15,000 and $22,000, respectively. Fixed assets held for sale at September 30, 2024 and 2023 in the amount of $16,000 and $0, respectively, are included in assets held for sale. Depreciation of assets ceases upon designation as held for sale.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2024
Goodwill
Goodwill	Note 7 –Goodwill Goodwill is as follows: ​ ​ ​ ​ ​ ​ Goodwill Balance on January 1, 2023 ​ $ 1,684,182 Balance on December 31, 2023 ​ 1,684,182 Goodwill associated with IMGX acquisition ​ 16,683,498 Goodwill reclassified as held for sale ​ $ (16,683,498) Balance on September 30, 2024 (unaudited) ​ $ 1,684,182 ​

Intangible Assets and In-Proces

Intangible Assets and In-Process R&D	9 Months Ended
	Sep. 30, 2024
Intangible Assets and In-Process R&D
Intangible Assets and In-Process R&D	Note 8 – Intangible Assets and In-Process R&D Intangible assets consist of IPR&D, patents, tradenames and trademarks acquired from ImmunogenX. As of September 30, 2024, Intangible assets have been reclassified as held for sale. Intangible assets and IPR&D activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ September 30, ​ Useful Life 2024 Patents 2 years ​ $ 140,000 Trademarks and trade names 6 years ​ 230,000 Less: accumulated amortization ​ ​ ​ (31,598) Intangible assets, net ​ ​ ​ 338,402 In-process R&D ​ ​ ​ 63,000,000 Intangible assets and in-process R&D reclassified as held for sale ​ ​ ​ ​ (63,338,402) Total intangible assets and in-process R&D, net ​ ​ ​ $ — ​

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Accrued Expenses
Accrued Expenses	Note 9 - Accrued Expenses Accrued expenses consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2024 December 31, ​ ​ (unaudited) ​ 2023 Professional fees ​ ​ 215,531 ​ ​ 253,577 Consulting fees ​ ​ — ​ ​ 75,972 Payroll and benefits ​ ​ 3,662 ​ ​ 495,741 Total accrued expenses ​ $ 219,193 ​ $ 825,290 ​ Accrued expenses in the amount of $2.2 million and $0 were reclassified as assets held for sale as of September 30, 2024 and 2023, respectively.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2024
Capital Stock
Capital Stock	Note 10 – Common Stock and Preferred Stock The Company’s amended and restated certificate of incorporation, as amended to date, (the “ Charter The Company had 4,741,964 and 1,560,998 shares of its Common Stock issued outstanding The Company had approximately 484.52 and 514.96 shares of Series B preferred stock issued outstanding The Company had 0 shares of Series C, Series D, Series E and Series F preferred stock issued and outstanding on September 30, 2024 and December 31, 2023. Most Favored Nations Exchange Right and Waiver Agreements In the event the Company effects any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, or a combination of units thereof (a “ Subsequent Financing Exchange Amount Series B Exchange Right Permanent Waiver Record Holders As of September 30, 2024, (i) holders of approximately 1,839.76 shares of Series B Preferred Stock with an aggregate Exchange Amount of approximately $14.4 million had previously elected to exercise their Series B Exchange Rights into Series C Preferred Stock, convertible into an aggregate of 395 shares of Common Stock (which conversion the Company has elected to make in full), and additional Investor Warrants exercisable for up to an aggregate of 395 shares of Common Stock, (ii) holders of approximately 160.62 shares of Series B Preferred Stock with an aggregate Exchange Amount of approximately $1.5 million had previously elected to exercise their Series B Exchange Rights into 128 shares of Common Stock with no warrants, and (iii) holders of approximately 30.91 shares of Series B Preferred Stock with an aggregate Exchange Amount of approximately $265,000 had previously elected to exercise their Series B Exchange Rights into 44 shares of Common Stock, and additional Series C Warrants exercisable for up to an aggregate of 44 shares of Common Stock. Mezzanine Equity Series G Preferred Stock The Company had 12,373.226 and 0 shares of Series G stock issued and outstanding December 31, 2023 On March 13, 2024, the Company issued 12,373.226 shares of Series G Preferred stock in connection with the IMGX Merger. The following is a summary of the principal terms of the Series G Preferred Stock as set forth in the Certificate of Designation of the Series G Preferred Stock: General; Transferability Conversion The Series G Preferred Stock is redeemable for cash at the option of the holder thereof at any time following the date that is six months after the initial issuance of the Series G Preferred Stock (without regard to the lack of obtaining the requisite stockholder approval to convert the Series G Preferred Stock into Common Stock), at a price per share equal to the then-current fair value of the Series G Preferred Stock, which shall be the last reported closing sale price of the Company’s Common Stock as reported on the Nasdaq Stock Market as of the trading day immediately prior to the conversion event. As such, Series G Preferred Stock is classified as Mezzanine Equity on the balance sheet. Voting Rights Liquidation Preference Dividend Rights Redemption Trading Market. At The Market Agreement with H.C. Wainwright On May 26, 2021, the Company entered into an At The Market Offering Agreement (the “ ATM Agreement Wainwright July 2024 Inducement Offering On July 10, 2024, the Company entered into a warrant exercise inducement offer letter (the “ Inducement Letter Holder Existing Warrants Existing Warrant Shares Inducement Warrants Inducement Warrant Shares Roth May 2024 Registered Direct Offering On May 14, 2024, the Company completed a Registered Direct Offering (the “ May 2024 Offering May 2024 Pre-Funded Warrants May 2024 Warrants The Company received gross proceeds of approximately $1.1 million less placement agent’s fees and other offering expenses of approximately $0.2 million. March 2024 Registered Direct Offering On March 6, 2024, the Company completed a Registered Direct Offering (the “ March 2024 Offering March 2024 Pre-Funded Warrants March 2024 Warrants September 2023 Inducement Offering On September 14, 2023, the Company entered into warrant exercise inducement offer letters with certain holders (the “ September 2023 Holders September 2023 Existing Warrants September 2023 Inducement Warrants September 2023 Inducement Warrant Shares September 2023 Inducement Offering July 2023 Offering On July 21, 2023, the Company completed an offering (the “ July 2023 Offering July 2023 Pre-Funded Warrants July 2023 Warrants June 2023 Inducement Offering On June 13, 2023, the Company entered into warrant exercise inducement offer letters with certain holders (the “ Holders Existing Warrants Inducement Warrants Inducement Warrant Shares June 2023 Inducement Offering Roth March 2023 Private Placement On March 15, 2023, the Company completed a private placement offering (the “ March 2023 Offering March 2023 Pre-Funded Warrants March 2023 Warrants Common Stock Issuances Issuances for the Three Months Ended September 30, 2024 During the three months ended September 30, 2024, the Company issued 1,762,674 shares of Common Stock under the July 2024 Inducement Offering for which the Company received net proceeds of approximately $1.7 million. During the three months ended September 30, 2024, the Company issued an aggregate of 38,182 shares of Common Stock upon the vesting of RSUs (See Note 12). Issuances for the Nine Months Ended September 30, 2024 During the nine months ended September 30, 2024, the Company issued 173,100 and 275,000 shares of Common Stock under the March 2024 Offering and May 2024 Offering, respectively, for which the Company received net proceeds of approximately $4.5 million. During the nine months ended September 30, 2024, the Company issued 1,762,674 shares of Common Stock under the July 2024 Inducement Offering for which the Company received net proceeds of approximately $1.7 million. During the nine months ended September 30, 2024, the Company issued an aggregate of 36,830 shares of Common Stock with a value of $2.3 million in connection with the IMGX acquisition. During the nine months ended September 30, 2024, the Company issued an aggregate of 18,475 shares of Common Stock with a value of $0.1 million to its financial advisors in connection with the IMGX acquisition. During the nine months ended September 30, 2024, the Company issued an aggregate of 443,525 shares of Common Stock upon the exercise of pre-funded warrants issued at a par value of $0.0001 (See Note 11). During the nine months ended September 30, 2024, the Company issued an aggregate of 27 shares of Common Stock upon the exchange of an aggregate of 30 shares of Series B Preferred Stock with a stated value of approximately $234,376 plus accrued dividends of approximately $70,429. During the nine months ended September 30, 2024, the Company issued an aggregate of 350,000 shares of its Common Stock to consultants with a grant date fair value of approximately $1,541,995 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the nine months ended September 30, 2024, the Company issued an aggregate of 121,335 shares of Common Stock upon the vesting of RSUs (See Note 12). Issuances for the Three Months Ended September 30, 2023 During the three months ended September 30, 2023, the Company issued 30,500 shares of Common Stock under the July 2023 Offering for which the Company received net proceeds of approximately $1.8 million. During the three months ended September 30, 2023, the Company issued 294,101 shares of Common Stock upon the exercise of an aggregate of 294,101 investor warrants for which the Company received net proceeds of approximately $3.7 million (See Note 11). During the three months ended September 30, 2023, the Company issued an aggregate of 133,750 shares of Common Stock upon the conversion of pre-funded warrants issued at a par value of $0.0001 . During the three months ended September 30, 2023, the Company issued an aggregate of 22 shares of Common Stock upon the exchange of an aggregate of 24.22 shares of Series B Preferred Stock with a stated value of approximately $186,500 plus accrued dividends of approximately $43,300 . During the three months ended September 30, 2023, the Company issued an aggregate of 2,500 shares of its Common Stock to consultants with a grant date fair value of approximately $76,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the three months ended September 30, 2023, the Company issued an aggregate of 1,851 shares of Common Stock upon the vesting RSUs (See Note 12). Issuances for the Nine Months Ended September 30, 2023 During the nine months ended September 30, 2023, the Company issued 6,400 shares of Common Stock under the March 2023 Offering for which the Company received net proceeds of approximately $3.7 million. During the nine months ended September 30, 2023, the Company issued 86,216 shares of Common Stock upon the exercise of an aggregate of 86,216 investor warrants for which the Company received net proceeds of approximately $2.2 million. During the nine months ended September 30, 2023, the Company issued 30,500 shares of Common Stock under the July 2023 Offering for which the Company received net proceeds of approximately $1.8 million. During the nine months ended September 30, 2023, the Company issued 294,101 shares of Common Stock upon the exercise of an aggregate of 294,101 investor warrants for which the Company received net proceeds of approximately $3.7 million. During the nine months ended September 30, 2023, the Company issued an aggregate of 199,974 shares of Common Stock upon the exercise of pre-funded warrants issued at a par value of $0.0001 . During the nine months ended September 30, 2023, the Company issued an aggregate of 26 shares of Common Stock upon the exchange of an aggregate of 28.45 shares of Series B Preferred Stock with a stated value of approximately $219,000 plus accrued dividends of approximately $49,500 . During the nine months ended September 30, 2023, the Company issued an aggregate of 2,500 shares of its Common Stock to consultants with a grant date fair value of approximately $76,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the nine months ended September 30, 2023, the Company issued an aggregate of 3,854 shares of Common Stock upon the vesting of RSUs. During the nine months ended September 30, 2023, the Company cancelled an aggregate of 148 shares of Common Stock in connection with the 1 -for-7 reverse stock split on January 18, 202 3.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2024
Warrants
Warrants	Note 11 – Warrant activity for the nine months ended September 30, 2024 and 2023 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise Price ​ Remaining ​ Warrants Per Share Term in Years Outstanding and exercisable on January 1, 2024 1,779,780 ​ $ 19.29 ​ 4.99 Issued 5,226,498 ​ ​ 1.87 ​ 4.85 Assumed from IMGX 127,680 ​ ​ 3.48 ​ 8.47 Expired ​ (3) ​ ​ 52,500.00 ​ — Exercised (2,206,199) ​ ​ 3.99 ​ 8.58 Warrants outstanding and exercisable on September 30, 2024 4,927,756 ​ $ 7.21 ​ 4.96 ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding and exercisable on January 1, 2023 108,797 ​ $ 383.20 ​ 5.50 Issued 1,369,940 ​ ​ 14.60 ​ 4.59 Expired (4) ​ ​ 15,475.80 ​ — Exercised (580,293) ​ ​ 19.20 ​ 4.72 Warrants outstanding and exercisable on September 30, 2023 898,440 ​ $ 47.60 ​ 4.89 ​ As of September 30, 2024, the outstanding warrants expire from 2024 through 2033. During the nine months ended September 30, 2024, the Company issued warrants to purchase 525,625 shares of the Company’s Common Stock and pre-funded warrants to purchase 352,525 shares of the Company’s Common Stock in connection with the March 2024 Offering, warrants to purchase 732,000 shares of the Company’s Common Stock and pre-funded warrants to purchase 91,000 shares of the Company’s Common Stock in connection with the May 2024 Offering , and warrants to purchase 3,525,348 shares of the Company’s Common Stock in connection with the July Inducement Offering (See Note 10). Additionally, the Company assumed warrants to purchase 127,680 shares of the Company’s Common Stock in connection with the IMGX acquisition. During the nine months ended September 30, 2024, an investor exercised pre-funded warrants to purchase 443,525 shares of the Company's Common Stock and common stock warrants to purchase 1,762,674 shares of the Company's Common Stock in connection with previous offerings. During the nine months ended September 30, 2023, the Company issued warrants to purchase 102,302 shares of the Company’s Common Stock and pre-funded warrants to purchase 44,751 shares of the Company’s Common Stock in connection with the March 2023 Offering, warrants to purchase 172,433 shares of the Company’s Common Stock in connection with the June 2023 Inducement Offering, warrants and pre-funded warrants to purchase 462,250 shares of the Company’s Common Stock in connection with the July 2023 Offering, and warrants to purchase 588,204 shares of the Company’s Common Stock in connection with the September 2023 Inducement Offering (See Note 10). During the nine months ended September 30, 2023, an investor exercised pre-funded warrants to purchase 199,974 shares of the Company's Common Stock and common stock warrants to purchase 380,319 shares of the Company's Common Stock in connection with previous offerings.

Equity Incentive Plan

Equity Incentive Plan	9 Months Ended
	Sep. 30, 2024
Equity Incentive Plan
Equity Incentive Plan	Note 12 – Equity Incentive Plan The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “ 2014 Plan 2020 Plan The 2020 Plan allows for the issuance of securities, including stock options to employees, Board members and consultants. The initial number of shares of Common Stock available for issuance under the 2020 Plan was 238 shares, which will, on January 1 of each calendar year, unless the Board decides otherwise, automatically increase to equal ten percent (10)% of the total number of shares of Common Stock outstanding on December 31 of the immediately preceding calendar year, calculated on an As Converted Basis. As Converted Shares include all outstanding shares of Common Stock and all shares of Common Stock issuable upon the conversion of outstanding preferred stock, warrants and other convertible securities, but will not include any shares of Common Stock issuable upon the exercise of options and other convertible securities issued pursuant to either the 2014 Plan, the 2020 Plan, or the IMGX Plan. The number of shares permitted to be issued as “incentive stock options” (“ ISOs On March 13, 2024, in connection with the IMGX acquisition, the Company assumed the IMGX Plan, including all 200,652 IMGX stock options immediately outstanding prior to the IMGX acquisition, with each becoming an option to purchase Common Stock, subject to adjustment. Such stock options were the only awards that had been made under the IMGX Plan as of the closing of the IMGX acquisition. The IMGX Plan was adopted and approved by the board of directors and stockholders of IMGX in 2021. Following the assumption of the IMGX Plan by the Company, no new awards have been or will be made under the IMGX Plan. As of January 1, 2024, the number of shares of Common Stock available for issuance under the 2020 Plan automatically increased to 334,078 under the 2020 Plan’s evergreen provision. As of September 30, 2024, there were an aggregate of 73 total shares available (but un-issuable) under the 2014 Plan, of which 27 are issued and outstanding, and 9 shares are reserved subject to issuance of restricted stock and RSUs. As of September 30, 2024, there were an aggregate of 350,000 total shares available (but un-issuable) under the IMGX 2021 Plan, of which 200,652 are issued and outstanding. As of September 30, 2024, 334,078 total shares were authorized under the 2020 Plan, of which 208,763 were issued and outstanding and 125,315 shares were available for potential issuances. During the nine months ended September 30, 2024 and 2023, stock option activity under the 2014 Plan, 2020 Plan, and IMGX 2021 Plan was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number ​ Exercise ​ Contract ​ Intrinsic ​ of Shares Price Life (Years) Value Outstanding at January 1, 2024 426 ​ $ 6,103.81 ​ 8.53 ​ $ — Assumed from ImmunogenX 200,652 ​ ​ 0.81 ​ 7.05 ​ ​ — Expired ​ (15) ​ ​ 18,720.80 ​ — ​ ​ — Outstanding at September 30, 2024 201,063 ​ $ 12.01 ​ 7.05 ​ $ — Exercisable at September 30, 2024 201,052 ​ $ 11.74 ​ 7.05 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at January 1, 2023 176 ​ $ 15,956.72 ​ 8.22 ​ $ — Granted 250 ​ ​ 74.60 ​ 9.40 ​ ​ — Outstanding at September 30, 2023 426 ​ $ 7,946.60 ​ 8.68 ​ $ — Exercisable at September 30, 2023 331 ​ $ 9,284.40 ​ 8.62 ​ $ — ​ During the nine months ended September 30, 2024, the Company assumed fully vested options to purchase 200,652 shares of the Company’s Common Stock issued under the IMGX 2021 Plan. During the nine months ended September 30, 2023, the Board approved the grant of options to purchase 250 shares of the Company’s Common Stock pursuant to the 2020 Plan. In general, options granted under the 2020 Plan vest monthly over a 36 For the nine months ended September 30, 2024 and 2023, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ 2024 2023 Contractual term (in years) 7.6 ​ 6.5 ​ Expected Volatility 110.35 % 98.80 % Risk-free interest rate 4.20 % 4.08 % Expected Dividend yield 0 % 0 % ​ Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock assumed during the nine months ended September 30, 2024 and 2023 was $6.32 and $61.00, respectively. Restricted Stock and Restricted Stock Units Restricted stock refers to shares of Common Stock subject to vesting based on certain service, performance, and market conditions. Restricted stock units (“ RSUs As of each September 30, 2024 and September 30, 2023, under the 2014 Plan, the Company had 1 share of restricted stock outstanding and an aggregate unrecognized restricted Common Stock expense of approximately $157,500, which will be recognized when vesting of certain milestones become probable. During the nine months ended September 30, 2024 and 2023, RSU activity under the 2020 Plan was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average Weighted-Average ​ ​ Number ​ Grant Date ​ Remaining Recognition ​ of Shares Fair Value Period (Years) Non-vested Outstanding at January 1, 2024 ​ 52,271 ​ $ 4.31 ​ 9.96 Awarded 150,421 ​ ​ 3.57 ​ — Vested ​ (133,401) ​ ​ 3.91 ​ — Cancelled (52,225) ​ 3.32 — Non-vested Outstanding at September 30, 2024 17,066 ​ $ 3.86 0.85 ​ ​ ​ ​ ​ ​ ​ ​ Non-vested Outstanding at January 1, 2023 ​ — ​ ​ — ​ — Awarded ​ 8,012 ​ $ 124.00 ​ — Vested ​ (5,680) ​ ​ 124.00 ​ — Canceled ​ (508) ​ ​ 124.00 ​ — Non-vested Outstanding at September 30, 2023 ​ 1,824 ​ $ 124.00 ​ 0.25 ​ During the nine months ended September 30, 2024 and 2023, the Board approved the grant of 150,421 and 8,012 RSUs, respectively. All grants of RSUs were pursuant to the 2020 Plan and typically vest quarterly over a one-year period. During the nine months ended September 30, 2024, 133,401 RSUs vested, of which 12,066 were issued in October 2024. During the nine months ended September 30, 2023, 5,680 RSUs vested, of which 1,826 were issued in October 2023. The total stock-based compensation expense for employees and non-employees is included in the accompanying condensed consolidated statements of operations and as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2024 2023 2024 2023 Research and development ​ $ 9,550 ​ $ 34,847 ​ $ 60,045 ​ $ 111,092 General and administrative ​ 174,096 ​ ​ 228,483 ​ ​ 526,851 ​ ​ 803,258 Total stock-based compensation expense ​ $ 183,646 ​ $ 263,330 ​ $ 586,896 ​ $ 914,350 ​ As of September 30, 2024, the Company had unrecognized stock-based compensation expense related to stock options and RSUs of approximately $78,000. Approximately $61,000 of this unrecognized expense will be recognized over the average remaining vesting term of the stock awards of 0.85 years. Approximately $17,000 of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable. Stock-based compensation related to IMGX for the three and nine months ended September 30, 2024 of approximately $6,000 and $19,000, respectively, is included in discontinued operations on the statement of operations. As of September 30, 2023, the Company had unrecognized stock-based compensation expense related to stock options and RSUs of approximately $0.6 million. Approximately $0.4 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock awards of 0.66 years. Approximately $0.2 million of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable.

Agreements

Agreements	9 Months Ended
	Sep. 30, 2024
Agreements
Agreements	Note 13 – Agreements License Agreement with Sanofi On September 13, 2023, the Company entered into a License Agreement with Sanofi, pursuant to which the Company received a license to obtain certain exclusive worldwide rights to develop and commercialize Capeserod, a selective 5-HT4 receptor partial agonist which the Company intends to repurpose and develop for gastrointestinal indications. The Company paid Sanofi an upfront payment of $0.5 million in October 2023 and Sanofi will be eligible to receive up to $46.0 million in potential development and regulatory milestone payments and up to $235.0 million in potential commercial milestone payments. Sanofi will also be eligible to receive mid-to-high single-digit royalties on net sales, as well as a percentage of sublicense and transfer revenues with respect to Capeserod. Sanofi will also have a right of first refusal with respect to Capeserod out-licensing transactions. The upfront payment of $0.5 million was recorded as research and development expense in the year ended December 31, 2023. Depending on the status of development at the time a contingent payment is recognized, the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized. The License Agreement shall expire on a country-by-country basis upon the later of: (i) the expiration of the last to expire valid claim of an applicable patent in such country covering such licensed product, (ii) the expiration of the regulatory exclusivity for such licensed product in the applicable country and (iii) the tenth anniversary of the date of first commercial sale of a licensed product in such country. Each party may terminate the License Agreement if the other party materially breaches its obligations under the License Agreement and fails to cure such material breach within 60 days from the date of such notice of breach, except in the case of payment breach, as to which the breaching party will have only a ten-day cure period. Sanofi may terminate the License Agreement upon any bankruptcy proceedings by the Company. The Company may terminate the License Agreement by providing Sanofi with at least 60 days prior written notice; provided, however, that Sanofi shall be entitled to any and all payments due and owed to Sanofi prior to the effective date of termination.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 14 – Leases The Company leases its offices under operating leases which are subject to various rent provisions and escalation clauses. The Company is a party to two real property operating leases for the rental of office space. The Company has office space of 3,472 square feet in Boca Raton, Florida that is used for its corporate headquarters with a term through August 31, 2026. The Company also has office space in Newport Beach, California with a term through April 30, 2025. In November 2024, the Company terminated its lease in Newport Beach, California. The Company’s leases expire at various dates through 2026. The escalation clauses are indeterminable and considered not material and have been excluded from minimum future annual rental payments. Lease expenses amounted to approximately $55,000 and $42,000 for the three months ended September 30, 2024 and 2023, respectively and $136,000 and $114,000 for the nine months ended September 30, 2024 and 2023, respectively. The weighted-average remaining lease term and weighted-average discount rate under operating leases as of September 30, 2024 are: ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2024 Lease term and discount rate ​ ​ Weighted-average remaining lease term (years) 1.9 ​ Weighted-average discount rate 7.00 % ​ Maturities of operating lease liabilities as of September 30, 2024, were as follows: ​ ​ ​ ​ ​ 2024 (remainder of year) $ 21,815 2025 ​ 88,788 2026 ​ 60,593 Total lease payments ​ 171,196 Less imputed interest ​ (11,529) Present value of lease liabilities ​ $ 159,667 ​

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt
Debt	Note 15 – Debt Debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Related ​ Directors ​ ​ ​ ​ ​ party ​ ​ ​ and Officer’s ​ ​ ​ ​ Revolving ​ promissory ​ ​ ​ Liability ​ ​ ​ ​ line of credit ​ notes ​ EIDL loan ​ Insurance ​ Total Principal balance as of January 1, 2024 ​ $ — ​ $ — ​ $ — ​ $ 612,784 ​ $ 612,784 Additions ​ ​ 5,359,860 ​ ​ 1,000,000 ​ ​ 500,000 ​ ​ 31,798 ​ ​ 6,891,658 Payments ​ — ​ ​ — ​ ​ — ​ ​ (644,582) ​ ​ (644,582) Debt discount ​ — ​ ​ — ​ ​ (456,123) ​ ​ — ​ ​ (456,123) Reclassification to liabilities held for sale ​ ​ (5,359,860) ​ ​ (1,000,000) ​ ​ (43,877) ​ ​ — ​ ​ (6,403,737) Total debt as of September 30, 2024 ​ $ — ​ $ — ​ $ — ​ $ — ​ $ — ​ Revolving line of credit In connection with the IMGX acquisition, the Company assumed a revolving line of credit. In October 2022, ImmunogenX entered into a credit agreement, which allowed for a revolving line of credit (the “ Revolver prime rate First Amendment Second Amendment prime rate Promissory notes In connection with the IMGX acquisition, the Company assumed two promissory notes, one of which is with a related party. The notes are each in the amount of $0.5 million, accrue interest at a rate of the prime rate EIDL loan In connection with the IMGX acquisition, the Company assumed an Economic Injury Disaster Loan (“ EIDL Directors and Officer ’ s Liability Insurance On November 30, 2023, the Company entered into 9-month financing agreements for its directors and officer’s liability insurance, as well as other corporate insurances, in the amount of approximately $0.7 million that bears interest at an annual rate of 7.90%. In June 2024, approximately $32,000 was added to the financing agreement. Monthly payments going forward, including principal and interest, are approximately $0.1 million per month. The balance due under these financing agreements was $0 at September 30, 2024 and $0.6 million at December 31, 2023.

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2024
Net Loss per Common Share
Net Loss per Common Share	Note 16 – Net Loss per Common Share Basic net loss per share is computed by dividing net loss available to Common Stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. For the nine months ended September 30, 2024 stock options in the amount of 201,063 and warrants in the amount of 4,927,756 were excluded from the calculation of diluted net loss per share as they did not have a dilutive effect. All shares of Common Stock that may potentially be issued in the future are as follows: ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2024 ​ September 30, 2023 ​ (unaudited) (unaudited) Series G convertible preferred stock ​ 12,373,226 ​ — Common stock warrants 4,927,756 ​ 898,440 Stock options 201,063 ​ 426 RSUs not yet issued ​ 17,066 ​ 1,824 Series B convertible preferred stock (1) 135 ​ 154 Restricted stock not yet issued 4 ​ 8 Total shares of common stock issuable 17,519,250 ​ 900,852 (1) Series B convertible preferred stock is assumed to be converted at the rate of $32,340 per common share, which is the conversion price as of September 30, 2024.

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2024
Employee Benefit Plans
Employee Benefit Plans	Note 17 - Employee Benefit Plans 401(k) Plan Since 2015, the Company has sponsored a multiple employer defined contribution benefit plan, which complies with Section 401(k) of the Internal Revenue Code covering substantially all employees of the Company. All employees are eligible to participate in the plan. Employees may contribute from 1% to 100% of their compensation and the Company matches an amount equal to 100% on the first 6% of the employee contribution and may also make discretionary profit-sharing contributions. Employer contributions under this 401(k) plan amounted to approximately $17,000 and $21,000 for the three months ended September 30, 2024 and 2023, respectively, and approximately $84,000 and $68,000 for the nine months ended September 30, 2024 and 2023.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes
Income Taxes	Note 18 - Income Taxes The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. Although the Company believes that it has adequately reserved for uncertain tax positions (including interest and penalties), it can provide no assurance that the final tax outcome of these matters will not be materially different. The Company makes adjustments to these reserves in accordance with the income tax accounting guidance when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on the Company’s financial condition and operating results. Carryforward attributes that were generated in tax years prior to those that remain open for examination may still be adjusted by relevant tax authorities upon examination if they either have been, or will be, used in a future period. In applying the estimated annual effective tax rate approach prescribed under ASC 740 - 270 and based on present evidence and conclusions around the realizability of deferred tax assets, the Company determined that any deferred tax benefits related to the forecasted tax rate and pretax activity during the first half of 2024 and 2023 are neither more likely than not to be realized in the current year nor realizable as a deferred tax asset at the end of the year. Therefore, the appropriate amount of income tax benefit to recognize related to deferred tax assets generated during the nine months ended September 30, 2024 and 2023 is zero. The Company’s effective income tax rate was approximately 73% and 0% for the nine months ended September 30, 2024 and 2023, respectively. The income tax provision for interim periods is determined using an estimate of the annual effective tax rate adjusted for discrete items. The Company’s effective tax rate for the nine months ended September 30, 2024 differs from the applicable statutory tax rate primarily due to the impact of the accounting for the IMGX Merger during the period, which resulted in the release of a portion of the valuation allowance that had previously been recorded against the deferred tax assets of the Company, resulting in a $10.6 million income tax benefit for the nine months ended September 30, 2024. The change in valuation allowance was determined based on the weight of available evidence as of the present reporting period and accounted for by the Company pursuant to ASC 805 - 740 - 30 - 3 in the Statement of Operations. The Company’s effective tax rate for the nine months ended September 30, 2023 differs from the applicable statutory tax rate primarily due to the full valuation allowance recorded against its deferred tax assets during the period.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events
Subsequent Events	Note 19 - Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements except for the items noted below. Binding Term Sheet In November 2024, the Company entered into a binding term sheet (the “ Binding Term Sheet Journey Acquisition Lease Termination In November 2024, the Company terminated its lease in Newport Beach, California. Share Issuances In October 2024, the Company issued an aggregate of 12,066 shares of Common Stock upon the vesting of RSUs.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,580,971)	$ (3,434,158)	$ (5,821,067)	$ (11,694,043)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Significant Accounting Polici_2

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2024
Significant Accounting Policies and Recent Accounting Pronouncements
Use of Estimates	Use of Estimates The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.
Reverse Stock Split	Reverse Stock Split On December 18, 2023, the Company effected a reverse stock split, whereby every twenty On January 18, 2023, the Company effected a reverse stock split, whereby every seven All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. All cash and cash equivalent balances were highly liquid at September 30, 2024 and December 31, 2023. As of September 30, 2024 and December 31, 2023, the Company has classified approximately $0.02 million as restricted cash.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At September 30, 2024 the Company had approximately $0.4 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.
Fair Value Measurements	Fair Value Measurements The Company follows Accounting Standards Codification ( ASC ( ASC 820 As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.
Goodwill	Goodwill Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through September 30, 2024 related to goodwill. ​
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment ( ASC 360
Income Taxes	Income Taxes Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ ASC 740 The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At September 30, 2024 and 2023, the Company does not have any significant uncertain tax positions.
Leases	Leases Leases are recorded on the balance sheet as right of use assets and lease obligations. Lease liabilities are recognized based on the present value of the future minimum lease payments over the least term at the commencement date. Leases with a term of 12 months or less at inception are expensed monthly over the lease term. The lease term is determined by assuming the exercise of renewal options that are reasonably certain. The implicit interest rate or the incremental borrowing rate is used in determining the present value of future payments.
Research and Development	Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“ CROs CDMOs CMC Research and Development – The Company records intellectual property acquired in business acquisitions that has not reached technological feasibility and which has no alternative future use, as In-Process R&D (“ IPR&D ​ Intangible assets related to IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off, and the Company will record a noncash impairment loss on its Consolidated Statements of Operations. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. The impairment test for indefinite-lived intangible assets is a one-step test that compares the fair value of the intangible asset to its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to the excess. The Company has not recognized any impairment charges through September 30, 2024 related to IPR&D. For tax purposes, intangible assets related to IPR&D are considered indefinite-lived intangible assets.
Stock-Based Compensation	Stock-Based Compensation The Company’s board of directors (the “ Board 2014 Plan 2020 Plan IMGX Plan ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.
Assets Held for Sale and Discontinued Operations	Assets Held for Sale and Discontinued Operations Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the condensed consolidated balance sheet. A newly acquired business in a business combination that has met the held for sale criteria should be measured at fair value less costs to sell. This is because the business has been recently acquired and its carrying value has been adjusted to its fair value. Depreciation and amortization of assets cease upon designation as held for sale. Discontinued operations comprise activities that were disposed of, discontinued or held for sale at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes, and represent a strategic business shift having a major effect on the Company’s operations and financial results according to ASC Topic 205, Presentation of Financial Statements. Additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations are included in Note 4.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has evaluated recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective, will not have a material impact on the Company’s financial position or results of operations upon adoption.

Business Acquisition (Tables)

Business Acquisition (Tables)	9 Months Ended
	Sep. 30, 2024
Business Acquisition
Schedule of preliminary fair value of the consideration	​ ​ ​ ​ ​ ​ Amount Common stock issued to ImmunogenX stockholders ​ $ 240,500 Replacement options ​ 1,271,000 Replacement warrants ​ 789,000 Preferred stock issued to ImmunogenX stockholders ​ 57,790,474 Total consideration paid ​ $ 60,090,974
Schedule of preliminary purchase price allocation	​ ​ ​ ​ ​ Assets acquired: ​ ​ Cash and cash equivalents ​ $ 88,169 Prepaid expenses and other current assets ​ 3,131,929 Property and equipment, net ​ 18,963 Intangibles ​ 63,370,000 Operating lease right-of-use assets ​ 4,232 Total assets ​ $ 66,613,293 Liabilities assumed: ​ Accounts payable ​ 916,209 Accrued expenses and other current liabilities ​ 2,131,439 Long term debt ​ 6,397,889 Deferred tax liability ​ 13,760,280 Total liabilities ​ $ 23,205,817 Goodwill recorded: ​ ​ ​ Goodwill ​ $ 16,683,498 Net assets acquired ​ $ 60,090,974
Schedule of intangible assets acquired	​ ​ ​ ​ ​ ​ ​ ​ Estimated Acquisition Date Intangible Asset ​ Useful Life ​ Fair Value Patents 2 years ​ $ 140,000 Trade names and trademarks 6 years ​ 230,000 IPR&D – Latiglutenase Indefinite ​ 54,000,000 IPR&D - CypCel Indefinite ​ $ 9,000,000
Schedule of pro forma results	​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Nine Months ​ ​ Ended September 30, 2024 ​ Ended September 30, 2024 Operating expenses ​ $ 1,892,607 ​ $ 14,417,763 Loss before income tax benefit ​ (1,895,252) ​ (14,424,947) Loss from discontinued operations ​ (685,719) ​ (9,374,674) Net loss applicable to common shareholders ​ ​ (2,665,603) ​ ​ (13,345,757) ​ ​ ​ ​ ​ ​ ​ Basic and diluted weighted average shares outstanding ​ 4,552,019 ​ 3,005,055 Loss per share - basic and diluted ​ $ (0.59) ​ $ (4.44) ​

Discontinued Operations and A_2

Discontinued Operations and Assets and Liabilities Held for Sale (Tables)	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Assets and Liabilities Held for Sale
Schedule of loss from discontinued operations and assets and liabilities associated with discontinued operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2024 2023 2024 2023 Operating expenses: ​ ​ ​ ​ Research and development expenses ​ $ 301,661 ​ $ — ​ $ 1,225,533 ​ $ — General and administrative expenses ​ 76,971 ​ — ​ 152,187 ​ — Total operating expenses ​ 378,632 ​ — ​ 1,377,720 ​ — Interest expense ​ (305,614) ​ — ​ (670,296) ​ — Other (expense) income ​ (1,473) ​ — ​ 47,256 ​ — Loss from discontinued operations ​ $ (685,719) ​ $ — ​ $ (2,000,760) ​ $ — ​ The assets and liabilities associated with discontinued operations consist of the following as of September 30, 2024: ​ ​ ​ ​ Assets held for sale: ​ Prepaid expenses and other current assets ​ $ 3,131,929 Property and equipment, net ​ 16,180 Goodwill and intangible assets ​ 80,021,900 Total assets held for sale ​ $ 83,170,009 Liabilities held for sale: ​ Accounts payable ​ $ 156,086 Accrued expenses and other current liabilities ​ 2,202,798 Debt ​ 6,403,737 Deferred tax liability ​ ​ 3,155,640 Total liabilities held for sale ​ $ 11,918,261

Fair Value Disclosures (Tables)

Fair Value Disclosures (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures
Schedule of fair value of the Company's financial instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measured at Reporting Date ​ ​ ​ ​ ​ ​ ​ ​ Using ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount Level 1 Level 2 Level 3 Fair Value September 30, 2024 (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 12,573 ​ $ 12,573 ​ $ — ​ $ — ​ $ 12,573 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 12,131 ​ $ 12,131 ​ $ — ​ $ — ​ $ 12,131 Note payable ​ ​ 612,784 ​ ​ — ​ ​ 612,784 ​ $ — ​ ​ 612,784

Property, Equipment and Lease_2

Property, Equipment and Leasehold Improvements (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Equipment and Leasehold Improvements
Schedule of property, equipment and leasehold improvements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2024 December 31, ​ ​ (unaudited) ​ 2023 Computer equipment and software ​ $ 11,540 ​ $ 11,540 Office equipment ​ 48,278 ​ 48,278 Leasehold improvements ​ 28,000 ​ 28,000 Total property, equipment and leasehold improvements ​ 87,818 ​ 87,818 Less accumulated depreciation ​ (87,818) ​ (73,253) Property, equipment and leasehold improvements, net ​ $ — ​ $ 14,565

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill
Schedule of goodwill	​ ​ ​ ​ ​ ​ Goodwill Balance on January 1, 2023 ​ $ 1,684,182 Balance on December 31, 2023 ​ 1,684,182 Goodwill associated with IMGX acquisition ​ 16,683,498 Goodwill reclassified as held for sale ​ $ (16,683,498) Balance on September 30, 2024 (unaudited) ​ $ 1,684,182 ​

Intangible Assets and In-Proc_2

Intangible Assets and In-Process R&D (Tables)	9 Months Ended
	Sep. 30, 2024
Intangible Assets and In-Process R&D
Summary of patents, tradenames and trademarks, intangible assets and in-process R&D from IMGX	​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ September 30, ​ Useful Life 2024 Patents 2 years ​ $ 140,000 Trademarks and trade names 6 years ​ 230,000 Less: accumulated amortization ​ ​ ​ (31,598) Intangible assets, net ​ ​ ​ 338,402 In-process R&D ​ ​ ​ 63,000,000 Intangible assets and in-process R&D reclassified as held for sale ​ ​ ​ ​ (63,338,402) Total intangible assets and in-process R&D, net ​ ​ ​ $ — ​

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Accrued Expenses
Schedule of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2024 December 31, ​ ​ (unaudited) ​ 2023 Professional fees ​ ​ 215,531 ​ ​ 253,577 Consulting fees ​ ​ — ​ ​ 75,972 Payroll and benefits ​ ​ 3,662 ​ ​ 495,741 Total accrued expenses ​ $ 219,193 ​ $ 825,290

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Warrants
Schedule of warrant activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise Price ​ Remaining ​ Warrants Per Share Term in Years Outstanding and exercisable on January 1, 2024 1,779,780 ​ $ 19.29 ​ 4.99 Issued 5,226,498 ​ ​ 1.87 ​ 4.85 Assumed from IMGX 127,680 ​ ​ 3.48 ​ 8.47 Expired ​ (3) ​ ​ 52,500.00 ​ — Exercised (2,206,199) ​ ​ 3.99 ​ 8.58 Warrants outstanding and exercisable on September 30, 2024 4,927,756 ​ $ 7.21 ​ 4.96 ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding and exercisable on January 1, 2023 108,797 ​ $ 383.20 ​ 5.50 Issued 1,369,940 ​ ​ 14.60 ​ 4.59 Expired (4) ​ ​ 15,475.80 ​ — Exercised (580,293) ​ ​ 19.20 ​ 4.72 Warrants outstanding and exercisable on September 30, 2023 898,440 ​ $ 47.60 ​ 4.89

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2024
Equity Incentive Plan
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number ​ Exercise ​ Contract ​ Intrinsic ​ of Shares Price Life (Years) Value Outstanding at January 1, 2024 426 ​ $ 6,103.81 ​ 8.53 ​ $ — Assumed from ImmunogenX 200,652 ​ ​ 0.81 ​ 7.05 ​ ​ — Expired ​ (15) ​ ​ 18,720.80 ​ — ​ ​ — Outstanding at September 30, 2024 201,063 ​ $ 12.01 ​ 7.05 ​ $ — Exercisable at September 30, 2024 201,052 ​ $ 11.74 ​ 7.05 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at January 1, 2023 176 ​ $ 15,956.72 ​ 8.22 ​ $ — Granted 250 ​ ​ 74.60 ​ 9.40 ​ ​ — Outstanding at September 30, 2023 426 ​ $ 7,946.60 ​ 8.68 ​ $ — Exercisable at September 30, 2023 331 ​ $ 9,284.40 ​ 8.62 ​ $ —
Schedule of option pricing model with the following weighted-average assumptions	​ ​ ​ ​ ​ ​ ​ ​ 2024 2023 Contractual term (in years) 7.6 ​ 6.5 ​ Expected Volatility 110.35 % 98.80 % Risk-free interest rate 4.20 % 4.08 % Expected Dividend yield 0 % 0 %
Schedule of RSU activity under the 2020 Plan	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average Weighted-Average ​ ​ Number ​ Grant Date ​ Remaining Recognition ​ of Shares Fair Value Period (Years) Non-vested Outstanding at January 1, 2024 ​ 52,271 ​ $ 4.31 ​ 9.96 Awarded 150,421 ​ ​ 3.57 ​ — Vested ​ (133,401) ​ ​ 3.91 ​ — Cancelled (52,225) ​ 3.32 — Non-vested Outstanding at September 30, 2024 17,066 ​ $ 3.86 0.85 ​ ​ ​ ​ ​ ​ ​ ​ Non-vested Outstanding at January 1, 2023 ​ — ​ ​ — ​ — Awarded ​ 8,012 ​ $ 124.00 ​ — Vested ​ (5,680) ​ ​ 124.00 ​ — Canceled ​ (508) ​ ​ 124.00 ​ — Non-vested Outstanding at September 30, 2023 ​ 1,824 ​ $ 124.00 ​ 0.25
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2024 2023 2024 2023 Research and development ​ $ 9,550 ​ $ 34,847 ​ $ 60,045 ​ $ 111,092 General and administrative ​ 174,096 ​ ​ 228,483 ​ ​ 526,851 ​ ​ 803,258 Total stock-based compensation expense ​ $ 183,646 ​ $ 263,330 ​ $ 586,896 ​ $ 914,350

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of weighted-average remaining lease term and weighted-average discount rate under operating leases	​ ​ ​ ​ ​ ​ ​ September 30, ​ 2024 Lease term and discount rate ​ ​ Weighted-average remaining lease term (years) 1.9 ​ Weighted-average discount rate 7.00 %
Schedule of maturities of operating lease liabilities	Maturities of operating lease liabilities as of September 30, 2024, were as follows: ​ ​ ​ ​ ​ 2024 (remainder of year) $ 21,815 2025 ​ 88,788 2026 ​ 60,593 Total lease payments ​ 171,196 Less imputed interest ​ (11,529) Present value of lease liabilities ​ $ 159,667 ​

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt
Schedule of debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Related ​ Directors ​ ​ ​ ​ ​ party ​ ​ ​ and Officer’s ​ ​ ​ ​ Revolving ​ promissory ​ ​ ​ Liability ​ ​ ​ ​ line of credit ​ notes ​ EIDL loan ​ Insurance ​ Total Principal balance as of January 1, 2024 ​ $ — ​ $ — ​ $ — ​ $ 612,784 ​ $ 612,784 Additions ​ ​ 5,359,860 ​ ​ 1,000,000 ​ ​ 500,000 ​ ​ 31,798 ​ ​ 6,891,658 Payments ​ — ​ ​ — ​ ​ — ​ ​ (644,582) ​ ​ (644,582) Debt discount ​ — ​ ​ — ​ ​ (456,123) ​ ​ — ​ ​ (456,123) Reclassification to liabilities held for sale ​ ​ (5,359,860) ​ ​ (1,000,000) ​ ​ (43,877) ​ ​ — ​ ​ (6,403,737) Total debt as of September 30, 2024 ​ $ — ​ $ — ​ $ — ​ $ — ​ $ —

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2024
Net Loss per Common Share
Schedule of Common Stock that may potentially be issued in the future	​ ​ ​ ​ ​ ​ ​ ​ September 30, 2024 ​ September 30, 2023 ​ (unaudited) (unaudited) Series G convertible preferred stock ​ 12,373,226 ​ — Common stock warrants 4,927,756 ​ 898,440 Stock options 201,063 ​ 426 RSUs not yet issued ​ 17,066 ​ 1,824 Series B convertible preferred stock (1) 135 ​ 154 Restricted stock not yet issued 4 ​ 8 Total shares of common stock issuable 17,519,250 ​ 900,852 (1) Series B convertible preferred stock is assumed to be converted at the rate of $32,340 per common share, which is the conversion price as of September 30, 2024.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
The Company and Basis of Presentation
Cash and cash equivalents	$ 366,788	$ 3,711,770
Accumulated deficit	$ (190,149,739)	$ (184,328,672)

Significant Accounting Polici_3

Significant Accounting Policies and Recent Accounting Pronouncements (Details) $ in Thousands			9 Months Ended
	Dec. 18, 2023	Jan. 18, 2023	Sep. 30, 2023	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Significant Accounting Policies and Recent Accounting Pronouncements
Reverse stock split ratio	0.05	0.143	0.143
Restricted cash				$ 20	$ 20
Cash in US banks in excess of FDIC insurance limits				$ 400

Business Acquisition (Details)

Business Acquisition (Details)		7 Months Ended
	Mar. 13, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) shares	Dec. 31, 2023 shares
Business Acquisition
Common stock. Shares outstanding		4,741,964	1,560,998
Common stock, shares issued (in shares)		4,741,964	1,560,998
IMGX
Business Acquisition
Share issuable per each share of preferred stock converted	1,000
Transaction costs | $	$ 5,456,038
Amount of advisory fees included in transaction cost | $	4,000,000
Preliminary fair value of consideration amount | $	$ 60,100,000
Net losses of acquiree from the date of acquisition | $		$ 2,000,000
IMGX | Common Stock
Business Acquisition
Number of shares issued	36,830
Common stock. Shares outstanding	2,303,135
Common stock, shares issued (in shares)	2,303,135
IMGX | Common Stock | Tungsten Partners LLC
Business Acquisition
Issuance of stock to financial advisors (in shares)	18,475
IMGX | Common Stock | Assumed Options
Business Acquisition
Number of shares issuable upon exercise of options or warrants	200,652
Exercise price per share | $ / shares	$ 0.81
IMGX | Common Stock | Assumed Warrants
Business Acquisition
Number of shares issuable upon exercise of options or warrants	127,680
IMGX | Common Stock | Assumed Warrants | Maximum
Business Acquisition
Exercise price per share | $ / shares	$ 3.92
IMGX | Common Stock | Assumed Warrants | Minimum
Business Acquisition
Exercise price per share | $ / shares	$ 3.03
IMGX | Series G convertible preferred stock
Business Acquisition
Number of shares issued	11,777.418
IMGX | Series G convertible preferred stock | Tungsten Partners LLC
Business Acquisition
Issuance of stock to financial advisors (in shares)	595.808

Business Acquisition - Consider

Business Acquisition - Consideration (Details) - IMGX	Mar. 13, 2024 USD ($)
Business Acquisition
Total consideration paid	$ 60,090,974
Replacement options
Business Acquisition
Replacement options/warrants	1,271,000
Replacement warrants
Business Acquisition
Replacement options/warrants	789,000
Common Stock
Business Acquisition
Stock issued to ImmunogenX stockholders	240,500
Series G convertible preferred stock
Business Acquisition
Stock issued to ImmunogenX stockholders	$ 57,790,474

Business Acquisition - Assets a

Business Acquisition - Assets acquired and the liabilities assumed (Details) - USD ($)	Sep. 30, 2024	Mar. 13, 2024	Dec. 31, 2023	Dec. 31, 2022
Liabilities assumed:
Goodwill	$ 1,684,182		$ 1,684,182	$ 1,684,182
IMGX
Assets acquired:
Cash and cash equivalents		$ 88,169
Prepaid expenses and other current assets		3,131,929
Property and equipment, net		18,963
Intangibles		63,370,000
Operating lease right-of-use assets		4,232
Total assets		66,613,293
Liabilities assumed:
Accounts payable		916,209
Accrued expenses and other current liabilities		2,131,439
Long term debt		6,397,889
Deferred tax liability		13,760,280
Total liabilities		23,205,817
Goodwill		16,683,498
Net assets acquired		$ 60,090,974

Business Acquisition - Amortiza

Business Acquisition - Amortization and associated estimated acquisition date fair values (Details) - IMGX	Mar. 13, 2024 USD ($)
Business Acquisition
Acquisition Date Fair Value	$ 63,370,000
IPR&D - Latiglutenase
Business Acquisition
Acquisition Date Fair Value	54,000,000
IPR&D - CypCel
Business Acquisition
Acquisition Date Fair Value	$ 9,000,000
Patents
Business Acquisition
Estimated Useful Life	2 years
Acquisition Date Fair Value	$ 140,000
Trade names and trademarks
Business Acquisition
Estimated Useful Life	6 years
Acquisition Date Fair Value	$ 230,000

Business Acquisition - Pro form

Business Acquisition - Pro forma results (Details) - IMGX - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Business Acquisition
Operating expenses	$ 1,892,607	$ 14,417,763
Loss before income tax benefit	(1,895,252)	(14,424,947)
Loss from discontinued operations	(685,719)	(9,374,674)
Net loss applicable to common shareholders	$ (2,665,603)	$ (13,345,757)
Basic weighted average shares outstanding	4,552,019	3,005,055
Diluted weighted average shares outstanding	4,552,019	3,005,055
Loss per share - basic	$ (0.59)	$ (4.44)
Loss per share - diluted	$ (0.59)	$ (4.44)

Discontinued Operations and A_3

Discontinued Operations and Assets and Liabilities Held for Sale (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Loss from discontinued operations
Loss from discontinued operations	$ (685,719)	$ (2,000,760)
Assets held for sale:
Property and equipment, net	16,000	16,000	$ 0
Total assets held for sale	83,170,009	83,170,009
Liabilities held for sale:
Total liabilities held for sale	11,918,261	11,918,261
IMGX | Disposal Group, Held-for-Sale
Loss from discontinued operations
Research and development expenses	301,661	1,225,533
General and administrative expenses	76,971	152,187
Total operating expenses	378,632	1,377,720
Interest expense	(305,614)	(670,296)
Other income		47,256
Other (expense)	(1,473)
Loss from discontinued operations	(685,719)	(2,000,760)
Assets held for sale:
Prepaid expenses and other current assets	3,131,929	3,131,929
Property and equipment, net	16,180	16,180
Goodwill and intangible assets	80,021,900	80,021,900
Total assets held for sale	83,170,009	83,170,009
Liabilities held for sale:
Accounts payable	156,086	156,086
Accrued expenses and other current liabilities	2,202,798	2,202,798
Debt	6,403,737	6,403,737
Deferred tax liability	3,155,640	3,155,640
Total liabilities held for sale	$ 11,918,261	$ 11,918,261

Fair Value Disclosures (Details

Fair Value Disclosures (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures
Money market funds	$ 366,788	$ 3,711,770
Note payable		612,784
Carrying Amount
Fair Value Disclosures
Note payable		612,784
Level 2
Fair Value Disclosures
Note payable		612,784
Money market funds
Fair Value Disclosures
Money market funds	12,573	12,131
Money market funds | Carrying Amount
Fair Value Disclosures
Money market funds	12,573	12,131
Money market funds | Level 1
Fair Value Disclosures
Money market funds	$ 12,573	$ 12,131

Property, Equipment and Lease_3

Property, Equipment and Leasehold Improvements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property, Equipment and Leasehold Improvements
Total property, equipment and leasehold improvements	$ 87,818		$ 87,818		$ 87,818
Less accumulated depreciation	(87,818)		(87,818)		(73,253)
Property, equipment and leasehold improvements, net					14,565
Depreciation	1,000	$ 7,000	15,000	$ 22,000
Fixed assets held for sale	16,000	$ 0	16,000	$ 0
Computer equipment and software
Property, Equipment and Leasehold Improvements
Total property, equipment and leasehold improvements	11,540		11,540		11,540
Office equipment
Property, Equipment and Leasehold Improvements
Total property, equipment and leasehold improvements	48,278		48,278		48,278
Leasehold improvements
Property, Equipment and Leasehold Improvements
Total property, equipment and leasehold improvements	$ 28,000		$ 28,000		$ 28,000

Goodwill (Details)

Goodwill (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Goodwill
Beginning balance	$ 1,684,182
Goodwill associated with IMGX acquisition	16,683,498
Goodwill reclassified as held for sale	(16,683,498)
Ending balance	$ 1,684,182

Intangible Assets and In-Proc_3

Intangible Assets and In-Process R&D (Details)	Sep. 30, 2024 USD ($)
Intangible Assets and In-Process R&D
Less: accumulated amortization	$ (31,598)
Intangible assets, net	338,402
Intangible assets and in-process R&D reclassified as held for sale	(63,338,402)
IPR&D
Intangible Assets and In-Process R&D
In-process R&D	63,000,000
Patents
Intangible Assets and In-Process R&D
Finite-lived intangible assets	$ 140,000
Finite-lived intangible assets, useful life (year)	2 years
Trademarks and trade names
Intangible Assets and In-Process R&D
Finite-lived intangible assets	$ 230,000
Finite-lived intangible assets, useful life (year)	6 years

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Accrued Expenses
Professional fees	$ 215,531	$ 253,577
Consulting fees		75,972
Payroll and benefits	3,662	495,741
Total accrued expenses	219,193	$ 825,290
Accrued expenses	$ 2,200,000		$ 0

Capital Stock (Details)

Capital Stock (Details)													3 Months Ended		9 Months Ended
	Jul. 10, 2024 USD ($) $ / shares shares	May 14, 2024 USD ($) $ / shares shares	Mar. 06, 2024 USD ($) $ / shares shares	Dec. 18, 2023	Sep. 14, 2023 USD ($) $ / shares shares	Jul. 21, 2023 USD ($) $ / shares shares	Jun. 13, 2023 USD ($) $ / shares shares	Mar. 15, 2023 USD ($) $ / shares shares	Jan. 18, 2023	May 24, 2022 USD ($)	May 12, 2022	May 26, 2021	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2024 shares	Mar. 13, 2024 shares	Dec. 31, 2023 $ / shares shares
Capital Stock
Common stock, shares authorized (in shares)													100,000,000		100,000,000				100,000,000
Common stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares authorized (in shares)													10,000,000		10,000,000
Preferred stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001
Common stock, shares, issued, total (in shares)													4,741,964		4,741,964				1,560,998
Common stock, shares outstanding (in shares)													4,741,964		4,741,964				1,560,998
Convertible preferred stock, shares issued upon conversion (in shares)																		1,000
Stock issued during period, value, acquisitions | $															$ 2,300,500
Issuance of stock to financial advisors | $															$ 120,648
Stock cancelled during period, shares, acquisitions (in shares)																148
Reverse stock split ratio				0.05					0.143							0.143
Proceeds from warrants exercise | $																$ 5,946,383
September 2023 Inducement Warrants
Capital Stock
Warrants to purchase of stock					294,101
Warrant exercise price | $ / shares					$ 8.60
Inducement warrants
Capital Stock
Warrants to purchase of stock													3,525,348		3,525,348
Consultants
Capital Stock
Stock issued during period, shares, settlement (in shares)														2,500	350,000	2,500
Stock issued during period, value, settlement | $														$ 76,000	$ 1,541,995	$ 76,000
Restricted Stock Units
Capital Stock
Issuance of common stock from RSU vest (in shares)													38,182
Conversion of stock, shares issued (in shares)														1,851	121,335	3,854
September 2023 Inducement Offering
Capital Stock
Proceeds from issuance of shares | $					$ 4,000,000
Payment made for services rendered | $					$ 200,000
September 2023 Inducement Offering | September 2023 Inducement Warrants
Capital Stock
Warrants to purchase of stock					588,204
Warrant exercise price | $ / shares					$ 2.50
At The Market Offering Agreement | Wainwright
Capital Stock
Stock sales agreement, commission on shares sold, percentage												3%
Stock sales agreement of shares authorized amount | $										$ 8,000,000
March 2024 Registered Direct Offering
Capital Stock
Stock issued during period, shares, new issues (in shares)			173,100
Number of common stock shares called by each warrant (in shares)			1
Warrants and rights outstanding, term (year)			5 years
Gross proceeds | $			$ 4,000,000
Other offering expenses | $			$ 400,000
Shares of common stock | $ / shares			$ 7.61
March 2024 Registered Direct Offering | March 2024 warrants
Capital Stock
Warrants to purchase of stock													525,625		525,625
Stock issued during period, shares, new issues (in shares)			525,625
Warrant exercise price | $ / shares			$ 7.48
March 2024 Registered Direct Offering | March 2024 pre-funded warrants
Capital Stock
Warrants to purchase of stock													352,525		352,525
Stock issued during period, shares, new issues (in shares)			352,525
Warrant exercise price | $ / shares			$ 0.0001
Private placement
Capital Stock
Number of common stock shares called by each warrant (in shares)								1
Warrants and rights outstanding, term (year)								5 years
Gross proceeds | $								$ 4,000,000
Other offering expenses | $								$ 300,000
Shares of common stock | $ / shares								$ 78.20
June 2023 inducement offering
Capital Stock
Warrants to purchase of stock							172,433
Warrant exercise price | $ / shares							$ 2.50
Proceeds from issuance of shares | $							$ 2,400,000
Payment made for services rendered | $							$ 200,000
June 2023 inducement offering | Existing warrants
Capital Stock
Warrants to purchase of stock							86,216							172,433		172,433
Warrant exercise price | $ / shares							$ 23
May 2024 registered direct offering
Capital Stock
Stock issued during period, shares, new issues (in shares)		275,000
Number of common stock shares called by each warrant (in shares)		1
Warrants and rights outstanding, term (year)		6 years
Gross proceeds | $		$ 1,100,000
Other offering expenses | $		$ 200,000
Shares of common stock | $ / shares		$ 2.95
May 2024 registered direct offering | May 2024 pre-funded warrants
Capital Stock
Warrants to purchase of stock													91,000		91,000
Stock issued during period, shares, new issues (in shares)		91,000
Warrant exercise price | $ / shares		$ 0.0001
May 2024 registered direct offering | May 2024 warrants
Capital Stock
Warrants to purchase of stock													732,000		732,000
Stock issued during period, shares, new issues (in shares)		732,000
Warrant exercise price | $ / shares		$ 2.70
July 2023 Offering
Capital Stock
Stock issued during period, shares, new issues (in shares)						30,500
Number of common stock shares called by each warrant (in shares)						1
Shares of common stock | $ / shares						$ 12.80
July 2023 Pre-Funded Warrants
Capital Stock
Stock issued during period, shares, new issues (in shares)						133,750
Number of common stock shares called by each warrant (in shares)						133,750
Warrant exercise price | $ / shares						$ 0.002
July 2023 Warrants
Capital Stock
Stock issued during period, shares, new issues (in shares)						328,500
Warrants and rights outstanding, term (year)						5 years
Warrant exercise price | $ / shares						$ 12.80
July 2024 Inducement Offering
Capital Stock
Proceeds from warrants exercise | $	$ 1,900,000
Amount paid for services | $	$ 100,000
July 2024 Inducement Offering | Existing warrants
Capital Stock
Warrants to purchase of stock	1,762,674
Warrant exercise price | $ / shares	$ 1.09
July 2024 Inducement Offering | Inducement warrants
Capital Stock
Warrants to purchase of stock	3,525,348
Public Offering
Capital Stock
Gross proceeds | $						$ 2,100,000
Other offering expenses | $						$ 300,000
Common stock warrants | September 2023 Inducement Offering
Capital Stock
Proceeds from Issuance of Common Stock | $														$ 3,700,000		$ 3,700,000
Common stock issued upon exercise of warrants (in shares)														294,101
Class of warrant or right, exercised during period (in shares)																294,101
Common stock warrants | June 2023 inducement offering
Capital Stock
Proceeds from Issuance of Common Stock | $																$ 2,200,000
Class of warrant or right, exercised during period (in shares)														294,101		86,216
Pre-funded warrants
Capital Stock
Exercise of pre-funded warrants into Common Stock														133,750	443,525	199,974
Par value per warrant | $ / shares														$ 0.0001	$ 0.0001	$ 0.0001
Series B convertible preferred stock
Capital Stock
Preferred stock, shares authorized (in shares)													5,194.81		5,194.81				5,194.81
Preferred stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares issued (in shares)													484.52		484.52				514.96
Preferred stock, shares outstanding (in shares)													484.52		484.52				514.96
Exchange Amount | $													$ 7,700		$ 7,700
Series B convertible preferred stock | Waiver
Capital Stock
Percentage of outstanding shares											81.30%
Series B convertible preferred stock | Series B Preferred Stock Converted into Common Stock
Capital Stock
Conversion of stock, shares converted (in shares)														24.22	30	28.45
Common stock issued upon conversion of preferred stock | $														$ 186,500	$ 234,376	$ 219,000
Conversion of stock, amount converted, accrued dividends | $														$ 43,300	70,429	$ 49,500
Series B Preferred Stock convertible into Series C Preferred Stock
Capital Stock
Exchange Amount | $													14,400,000		$ 14,400,000
Conversion of stock, shares converted (in shares)															1,839.76
Conversion of Series B preferred shares into common stock (in shares)															395
Series B Preferred Stock convertible into Series C Preferred Stock | Investor warrants
Capital Stock
Conversion of Series B preferred shares into common stock (in shares)															395
Series B Preferred Stock convertible into common stock with no warrants
Capital Stock
Exchange Amount | $													1,500,000		$ 1,500,000
Conversion of stock, shares converted (in shares)															160.62
Conversion of Series B preferred shares into common stock (in shares)															128
Series B Preferred Stock Convertible Into Common Stock With Series C Warrants
Capital Stock
Exchange Amount | $													$ 265,000		$ 265,000
Conversion of stock, shares converted (in shares)															30.91
Conversion of Series B preferred shares into common stock (in shares)															44
Series B Preferred Stock Convertible Into Common Stock With Series C Warrants | March 2024 Warrants
Capital Stock
Warrants to purchase of stock													44		44
Series C Preferred Stock
Capital Stock
Preferred stock, shares authorized (in shares)													75,000		75,000				75,000
Preferred stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares issued (in shares)													0		0		0		0
Preferred stock, shares outstanding (in shares)													0		0		0		0
Series C Preferred Stock | Private placement
Capital Stock
Number of common shares issuable upon conversion								44,751
Series D Preferred Stock
Capital Stock
Preferred stock, shares authorized (in shares)													150		150				150
Preferred stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares issued (in shares)													0		0				0
Preferred stock, shares outstanding (in shares)													0		0				0
Series D Preferred Stock | Private placement
Capital Stock
Stock issued during period, shares, new issues (in shares)								6,400
Preferred stock, convertible, conversion price (in dollars per share) | $ / shares								$ 0.002
Series G convertible preferred stock
Capital Stock
Temporary Equity, Shares Issued													12,373.226		12,373.226				0
Temporary Equity, Shares Outstanding													12,373.226		12,373.226				0
Series G convertible preferred stock | IMGX
Capital Stock
Temporary Equity, Shares Issued																		12,373.226
Series G Redeemable Preferred Stock
Capital Stock
Temporary Equity, Shares Issued													12,373.226		12,373.226				0
Temporary Equity, Shares Outstanding													12,373.226		12,373.226				0
Series E Preferred Stock
Capital Stock
Preferred stock, shares authorized (in shares)													150		150				150
Preferred stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares issued (in shares)													0		0				0
Preferred stock, shares outstanding (in shares)													0		0				0
Series E Preferred Stock | Private placement
Capital Stock
Number of common shares issuable upon conversion								102,302
Warrant exercise price | $ / shares								$ 73.20
Series F Preferred Stock
Capital Stock
Preferred stock, shares authorized (in shares)													7,000		7,000				7,000
Preferred stock, par or stated value per share (in dollars per share) | $ / shares													$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares issued (in shares)													0		0				0
Preferred stock, shares outstanding (in shares)													0		0				0
Common Stock
Capital Stock
Proceeds from Issuance of Common Stock | $															$ 4,500,000
Conversion of stock, shares issued (in shares)														22	27	26
Common Stock | IMGX
Capital Stock
Stock Issued During Period, Shares, Acquisitions (in shares)															36,830
Stock issued during period, value, acquisitions | $															$ 2,300,000
Issuance of stock to financial advisors (in shares)															18,475
Issuance of stock to financial advisors | $															$ 100,000
Common Stock | September 2023 Inducement Offering
Capital Stock
Common stock issued upon exercise of warrants (in shares)																294,101
Common Stock | March 2024 Registered Direct Offering
Capital Stock
Stock issued during period, shares, new issues (in shares)															173,100
Common Stock | July 2024 Inducement offering
Capital Stock
Proceeds from Issuance of Common Stock | $															$ 1,700,000
Common Stock | March 2023 offering
Capital Stock
Stock issued during period, shares, new issues (in shares)																6,400
Proceeds from Issuance of Common Stock | $																$ 3,700,000
Common Stock | June 2023 inducement offering
Capital Stock
Common stock issued upon exercise of warrants (in shares)														30,500		86,216
Common Stock | May 2024 registered direct offering
Capital Stock
Stock issued during period, shares, new issues (in shares)															275,000
Common Stock | July 2023 Offering
Capital Stock
Stock issued during period, shares, new issues (in shares)																30,500
Common Stock | July 2024 Inducement Offering
Capital Stock
Stock issued during period, shares, new issues (in shares)													1,762,674		1,762,674
Proceeds from Issuance of Common Stock | $													$ 1,700,000
Common Stock | Common stock warrants | July 2023 Offering
Capital Stock
Proceeds from Issuance of Common Stock | $														$ 1,800,000		$ 1,800,000
Maximum | Series G convertible preferred stock
Capital Stock
Preferred Stock, Beneficial Ownership Held, Percentage																		19.90%
Minimum | Series G convertible preferred stock
Capital Stock
Threshold limits of ownership percentage																		4.9

Warrants (Details)

Warrants (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	May 14, 2024	Mar. 06, 2024	Jun. 13, 2023
Number of Warrants
Outstanding and exercisable, beginning (in shares)	1,779,780	108,797	108,797
Issued (in shares)	5,226,498	1,369,940
Assumed from IMGX (in shares)	127,680
Expired during the period (in shares)	(3)	(4)
Exercised (in shares)	(2,206,199)	(580,293)
Warrants outstanding and exercisable, ending (in shares)	4,927,756	898,440	1,779,780	108,797
Weighted Average Exercise Price Per Share
Outstanding and exercisable, beginning (in dollars per share)	$ 19.29	$ 383.20	$ 383.20
Issued (in dollars per share)	1.87	14.60
Assumed from IMGX (in dollars per share)	3.48
Expired during the period (in dollars per share)	52,500	15,475.80
Exercised (in dollars per share)	3.99	19.20
Warrants outstanding and exercisable, ending (in dollars per share)	$ 7.21	$ 47.60	$ 19.29	$ 383.20
Weighted Average Remaining Term in Years
Outstanding and exercisable (in years)	4 years 11 months 15 days	4 years 10 months 20 days	4 years 11 months 26 days	5 years 6 months
Issued (in years)	4 years 10 months 6 days	4 years 7 months 2 days
Assumed from IMGX (in years)	8 years 5 months 19 days
Expired (in years)	0 years	0 years
Exercised (in years)	8 years 6 months 29 days	4 years 8 months 19 days
September 2023 Inducement Warrants
Number of Warrants
Assumed from IMGX (in shares)		588,204
July 2023 Inducement Offering [member]
Weighted Average Remaining Term in Years
Warrants to purchase of stock		462,250
June 2023 inducement offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock							172,433
Exercise price per share							$ 2.50
March 2024 pre-funded warrants | March 2024 registered direct offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock	352,525
Exercise price per share						$ 0.0001
March 2024 warrants | March 2024 registered direct offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock	525,625
Exercise price per share						$ 7.48
May 2024 pre-funded warrants | May 2024 registered direct offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock	91,000
Exercise price per share					$ 0.0001
May 2024 warrants | May 2024 registered direct offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock	732,000
Exercise price per share					$ 2.70
March 2023 pre-funded warrants | March 2023 registered direct offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock		44,751
March 2023 warrants | March 2023 registered direct offering | Common Stock
Weighted Average Remaining Term in Years
Warrants to purchase of stock		102,302
Existing warrants | June 2023 inducement offering
Weighted Average Remaining Term in Years
Warrants to purchase of stock		172,433					86,216
Exercise price per share							$ 23
Inducement warrants
Weighted Average Remaining Term in Years
Warrants to purchase of stock	3,525,348
Pre-funded warrants
Number of Warrants
Exercise of pre-funded warrants into Common Stock (in shares)	443,525	199,974
Common stock warrants | July 2024 Inducement offering
Number of Warrants
Exercise of pre-funded warrants into Common Stock (in shares)	1,762,674
Common stock warrants | July 2023 Inducement Offering [member]
Number of Warrants
Exercise of pre-funded warrants into Common Stock (in shares)		380,319

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - USD ($)		1 Months Ended		3 Months Ended	9 Months Ended
	Sep. 11, 2020	Oct. 31, 2024	Oct. 31, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Mar. 13, 2024	Jan. 01, 2024	Dec. 31, 2023
Equity Incentive Plan
Unrecognized stock-based compensation expense				$ 78,000	$ 78,000	$ 600,000
Stock-based compensation					586,896	914,350
Remaining term
Equity Incentive Plan
Unrecognized stock-based compensation expense				61,000	$ 61,000	$ 400,000
Average remaining vesting term of the stock options (in years)					10 months 6 days	7 months 28 days
Clinical, corporate milestones
Equity Incentive Plan
Unrecognized stock-based compensation expense				$ 17,000	$ 17,000	$ 200,000
Employee Stock Option
Equity Incentive Plan
Granted (in shares)					357
Restricted Stock Units | Subsequent events
Equity Incentive Plan
Issuance of common stock for vesting of RSUs		12,066
Stock option
Equity Incentive Plan
Weighted average fair value of warrants granted (in dollars per share)					$ 6.32	$ 61
2020 Equity Incentive Plan
Equity Incentive Plan
Shares available under equity incentive plan (in shares)	238			334,078	334,078			334,078
Percentage of common stock reserved for issuance equity incentive plan	10%
Options to purchase shares of common stock (in shares)				208,763	208,763
Shares reserved subject to issuance (in shares)				125,315	125,315
Options cancelled						250
Vesting period						36 months
2020 Equity Incentive Plan | Restricted Stock Units
Equity Incentive Plan
Vested in period (in shares)					133,401	5,680
Issuance of common stock for vesting of RSUs			1,826
Number of awards outstanding				17,066	17,066	1,824			52,271
Awarded (in shares)					150,421	8,012
Vesting period					1 year
Equity Incentive Plan 2014 | RSUs not yet issued
Equity Incentive Plan
Number of awards outstanding				1	1	1
Aggregate unrecognized restricted Common Stock expense				$ 157,500	$ 157,500	$ 157,500
Omnibus Equity Incentive Plan
Equity Incentive Plan
Shares available under equity incentive plan (in shares)				73	73
Options to purchase shares of common stock (in shares)				27	27
Omnibus Equity Incentive Plan | RSUs not yet issued
Equity Incentive Plan
Shares reserved subject to issuance (in shares)				9	9
IMGX 2021 plan
Equity Incentive Plan
Shares available under equity incentive plan (in shares)				350,000	350,000
Options to purchase shares of common stock (in shares)				200,652	200,652
Number of share options assumed in business combination issued					200,652
IMGX Plan
Equity Incentive Plan
Stock-based compensation				$ 6,000	$ 19,000
IMGX Plan | ImmunogenX
Equity Incentive Plan
Options to purchase shares of common stock (in shares)							200,652

Equity Incentive Plan - Stock o

Equity Incentive Plan - Stock option activity (Details) - Stock option - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Numbers of Shares
Granted (in shares)	357
Amended and Restated Omnibus Equity Incentive Plan 2014, Omnibus Equity Incentive Plan 2020 and IMGX 2021 Plan
Numbers of Shares
Outstanding at beginning (in shares)	426	176	176
Assumed from ImmunogenX (in shares)	200,652
Granted (in shares)		250
Expired (in shares)	(15)
Outstanding at ending (in shares)	201,063	426	426	176
Exercisable (in shares)	201,052	331
Average Exercise Price
Outstanding at beginning (in dollars per share)	$ 6,103.81	$ 15,956.72	$ 15,956.72
Assumed from ImmunogenX (in dollars per share)	0.81
Granted (in dollars per share)		74.60
Expired (in dollars per share)	18,720.80
Outstanding at ending (in dollars per share)	12.01	7,946.60	$ 6,103.81	$ 15,956.72
Exercisable (in dollars per share)	$ 11.74	$ 9,284.40
Remaining Contract Life (Years)
Stock option outstanding, remaining contractual life (Years)	7 years 18 days	8 years 8 months 4 days	8 years 6 months 10 days	8 years 2 months 19 days
Assumed from ImmunogenX (in years)	7 years 18 days
Granted (in years)		9 years 4 months 24 days
Exercisable (in years)	7 years 18 days	8 years 7 months 13 days

Equity Incentive Plan - Weighte

Equity Incentive Plan - Weighted-average assumptions (Details) - Stock option	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Equity Incentive Plan
Contractual term (in years)	7 years 7 months 6 days	6 years 6 months
Expected Volatility	110.35%	98.80%
Risk-free interest rate	4.20%	4.08%
Expected Dividend yield	0%	0%

Equity Incentive Plan - RSU act

Equity Incentive Plan - RSU activity under the 2020 Plan (Details) - 2020 Equity Incentive Plan - Restricted Stock Units - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Number of Shares
Outstanding at beginning (in shares)	52,271
Awarded (in shares)	150,421	8,012
Vested (in shares)	(133,401)	(5,680)
Canceled (shares)	(52,225)	(508)
Outstanding at ending (in shares)	17,066	1,824	52,271
Weighted-Average Grant Date Fair Value
Outstanding at beginning (in dollars per share)	$ 4.31
Awarded (in dollars per share)	3.57	$ 124
Vested (in dollars per share)	3.91	124
Canceled (in dollars per share)	3.32	124
Outstanding at ending (in dollars per share)	$ 3.86	$ 124	$ 4.31
Weighted-Average Remaining Recognition Period (Years)	10 months 6 days	3 months	9 years 11 months 15 days

Equity Incentive Plan - Total s

Equity Incentive Plan - Total stock-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Equity Incentive Plan
Total stock-based compensation expense	$ 183,646	$ 263,330	$ 586,896	$ 914,350
Research and development
Equity Incentive Plan
Total stock-based compensation expense	9,550	34,847	60,045	111,092
General and administrative
Equity Incentive Plan
Total stock-based compensation expense	$ 174,096	$ 228,483	$ 526,851	$ 803,258

Agreements (Details)

Agreements (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 13, 2023	Oct. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Agreements
Research and development expenses			$ 206,999	$ 1,011,055	$ 882,522	$ 3,725,833
License agreement
Agreements
Upfront payment made to the third party		$ 500,000
License agreement | Sanofi
Agreements
Research and development expenses							$ 500,000
Termination of contract, cure period					60 days
Termination of contract, cure period for payment breach					10 days
Number of days prior written notice to be issued					60 days
License agreement | Sanofi | Development and regulatory milestone
Agreements
Amount eligible to receive by third party	$ 46,000,000
License agreement | Sanofi | Commercial milestone
Agreements
Amount eligible to receive by third party	$ 235,000,000

Leases (Details)

Leases (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($) ft² property	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) ft² property	Sep. 30, 2023 USD ($)
Leases
Number of real property operating leases | property	2		2
Operating lease, expense | $	$ 55,000	$ 42,000	$ 136,000	$ 114,000
Boca Raton, Florida
Leases
Area of real estate property (Square Foot) | ft²	3,472		3,472

Leases - Weighted-average remai

Leases - Weighted-average remaining lease term and discount rate (Details)	Sep. 30, 2024
Leases
Weighted-average remaining lease term (years)	1 year 10 months 24 days
Weighted-average discount rate	7%

Leases - Maturities of operatin

Leases - Maturities of operating lease liabilities (Details)	Sep. 30, 2024 USD ($)
Leases
2024 (remainder of year)	$ 21,815
2025	88,788
2026	60,593
Total lease payments	171,196
Less imputed interest	(11,529)
Present value of lease liabilities	$ 159,667

Debt (Details)

Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 13, 2024	Dec. 31, 2023	Nov. 30, 2023
Debt
Debt instrument, face amount				$ 612,784
Additions	$ 6,891,658
Payments	(644,582)
Debt discount	(456,123)
Reclassification to liabilities held for sale	(6,403,737)
Revolving line of credit
Debt
Additions	5,359,860
Reclassification to liabilities held for sale	(5,359,860)
Related party promissory notes
Debt
Debt instrument, face amount	500,000
Additions	1,000,000
Reclassification to liabilities held for sale	(1,000,000)
EIDL loan
Debt
Debt instrument, face amount	500,000
Additions	500,000
Debt discount	(456,123)		$ (462,000)
Reclassification to liabilities held for sale	(43,877)
Directors and Officer's Liability Insurance
Debt
Debt instrument, face amount		$ 32,000		612,784	$ 700,000
Additions	31,798
Payments	(644,582)
Total debt as of September 30, 2024	$ 0			$ 600,000

Debt - Additional information (

Debt - Additional information (Details)			1 Months Ended		9 Months Ended
	Mar. 13, 2024 USD ($)	Nov. 30, 2023 USD ($)	Mar. 31, 2024 item	Oct. 31, 2022 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)
Debt
Amount of debt							$ 612,784
Debt discount					$ 456,123
Revolving line of credit
Debt
Maximum amount of borrowings				$ 6,000,000				$ 7,500,000
Spread on interest rate (in percent)	6%			4.50%
Investment, Variable Interest Rate, Type [Extensible Enumeration]	us-gaap:PrimeRateMember			us-gaap:PrimeRateMember
Related party promissory notes
Debt
Spread on interest rate (in percent)					4.50%
Investment, Variable Interest Rate, Type [Extensible Enumeration]					us-gaap:PrimeRateMember
Number of notes assumed | item			2
Amount of debt					$ 500,000
EIDL loan
Debt
Amount of debt					$ 500,000
Interest rate (in percent)					3.75%
Debt instrument, fair value	$ 38,000
Debt discount	$ 462,000				$ 456,123
Directors and Officer's Liability Insurance
Debt
Amount outstanding					0		600,000
Amount of debt		$ 700,000				$ 32,000	$ 612,784
Interest rate (in percent)		7.90%
Term of debt		9 months
Monthly payments, including principal and interest					$ 100,000

Net Loss per Common Share - (De

Net Loss per Common Share - (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net Loss per Common Share
Shares of common stock issuable	17,519,250	900,852
Stock option
Net Loss per Common Share
Shares of common stock issuable	201,063
Common stock warrants
Net Loss per Common Share
Shares of common stock issuable	4,927,756

Net Loss per Common Share - Com

Net Loss per Common Share - Common Stock that may potentially be issued (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net Loss per Common Share
Total shares of common stock issuable	17,519,250	900,852
Series G convertible preferred stock
Net Loss per Common Share
Total shares of common stock issuable	12,373,226
Common stock warrants
Net Loss per Common Share
Total shares of common stock issuable	4,927,756	898,440
Stock options
Net Loss per Common Share
Total shares of common stock issuable	201,063	426
RSUs not yet issued
Net Loss per Common Share
Total shares of common stock issuable	17,066	1,824
Series B convertible preferred stock
Net Loss per Common Share
Total shares of common stock issuable	135	154
Preferred stock, convertible, conversion price (in dollars per share)	$ 32,340
Restricted stock not yet issued
Net Loss per Common Share
Total shares of common stock issuable	4	8

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Benefit Plans
Defined contribution plan, employers matching contribution, annual vesting percentage			6%
Defined benefit plan, plan assets, contributions by employer	$ 17,000	$ 21,000	$ 84,000	$ 68,000
Minimum
Employee Benefit Plans
Defined contribution plan, maximum annual contributions per employee, percent			1%
Maximum
Employee Benefit Plans
Defined contribution plan, maximum annual contributions per employee, percent			100%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Taxes
Deferred tax assets	$ 0	$ 0
Effective income tax	73%	0%
Income tax benefit	$ (10,600,000)

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent events - USD ($) $ in Millions		1 Months Ended
	Nov. 08, 2024	Oct. 31, 2024
Journey Therapeutics, Inc.
Subsequent Events
Equity interest	100%
Proceeds from issuance of shares	$ 5
Percentage of return on equity interest	99%
Restricted Stock Units
Subsequent Events
Issuance of common stock for vesting of RSUs		12,066